Entities

Executive assistant and office manager at GreatPoint Ventures, with published experience supporting founders and executives.

Partner at GreatPoint Ventures, whose biography says he joined in 2022. His entrepreneurial background includes founding and leading Dispatch and earlier work with GreatPoint Energy. Historical outside affiliations do not establish separate current roles or personal investments.

Cecilia Braggiotti is venture partner at Insiders VC, an operator, investor and adviser with experience across technology, healthcare and consumer businesses. Her earlier career included McKinsey, private equity, hedge funds and AIcompanyAfiniti. ArsenaleGroup’s own biography records degrees from CassBusinessSchool, LondonBusinessSchool and INSEAD, plus Stanfordexecutivestudy. Her outside board and advisory affiliations are separate from institutional venture cash and do not automatically identify Insiders portfolio investments.

Partner at GreatPoint Ventures, with a published joining year of 2021. His investment work includes healthcare infrastructure and payer/provider workflows. He studied mathematics and economics at Kenyon College.

Executive assistant at GreatPoint Ventures. Her published background includes support roles at Kleiner Perkins, Apple and NeXT.

Partner at GreatPoint Ventures, with a published joining year of 2023. His investment background includes IAC and a focus on vertical software, marketplaces and financial technology.

Lee Greening is finance director at Insiders VC, according to its current official six-person team directory. He previously served as finance director at FACEIT, corroborated by the founder-compensation research published by Index Ventures. His current role supports the venture platform’s financial operations; he is not described as a general partner or investment committee member without primary proof.

Mirta Rotondo is brand and experience director at Insiders VC. She is a design leader and branding adviser who previously built and led a40person experience design team at TrueLayer. Her own biography describes building Mindmapp, an AI-assisted emotional organisation product, and design leadership work across branding and product experience. She holds qualifications in art direction from IEDRome and illustration from the Academy of Art University inSanFrancisco.

Operations manager at GreatPoint Ventures. His published professional background includes fund administration at Standish.

Chief operating officer of GreatPoint Ventures. Her published responsibilities span finance, legal matters, fund administration, human resources and investor relations. Her career background includes Timshel.

Jeff Forrest, also known professionally as Jeffrey Forrest, is investment partner at Insiders VC in London. His self-published professional profile confirms the exact manager affiliation and London Business School study from2020 to2022. His own posts describe supporting venture investments including enterpriseAIcompanyTwin1. He is distinct from the similarly named recording engineer, CGIconsultant and other financial professionals; unverifiable prior-employer details are omitted.

GreatPoint Ventures managing partner with a focus on enterprise computing and the intersection of computer science and life sciences. His published background includes founding CAPP Medical, CiberMed and Xsigo, and early technology leadership at Juniper Networks.

General partner of GreatPoint Ventures. His own biography says he joined in 2021 and invests in enterprise AI and automation, data infrastructure, financial technology and commerce infrastructure. Previous roles include Green Bay Ventures, CapitalG and Goldman Sachs.

Michele Attisani is co-founder and general partner of Insiders VC. He co-founded FACEIT, helped build its gaming community and international business, and participated in the2022 transaction creating ESL FACEIT Group. His earlier founder career and personal angel investments are distinct from the current venture platform’s institutional investments. Insiders provides operating support to early-stage founders across AI, software and other technology businesses.

Niccolo Maisto is co-founder and general partner of Insiders VC. He co-founded gaming platform FACEIT with Michele Attisani and helped scale it to more than30million users. FACEIT combined with ESL in2022 to form ESL FACEIT Group in a transaction the firm describes atUSD1.5billion; that historic company transaction is not capital raised by Insiders. He now supports early-stage founders using operating and company-building experience.

Insiders is an early-stage venture investment platform founded by FACEIT entrepreneurs Niccolo Maisto and Michele Attisani. They bring experience building and scaling a global gaming business and its2022 transaction forming ESL FACEIT Group. The London-based platform invests as a follower and supports founders through operating experience and its network. Its public portfolio covers applied artificial intelligence, enterprise and developer software, AI infrastructure, fintech and healthcare, including hormone-monitoring wearable company Clair Health. The official website is operated by UK Insiders Ventures Advisors Limited (company16260673, incorporated18February2025), an appointed representative under FCA reference1034159 of Gen II Management Company (UK) Limited (FRN438890). The brand, UK advisory company and Jersey fund/general-partner entities are distinguished; no claim that the advisory company personally owns every fund investment is made. The six-person published roster comprises two general partners, an investment partner, venture partner, brand and experience director, and finance director. The platform is distinct from insiders.ventures, the Georgian crypto investor, and The Insiders Fund, the US public-equity strategy. Founder proceeds and prior FACEIT financing or acquisition values are not Insiders fund cash. Public portfolio stage labels do not identify exact priced financing rounds; personal angel investments remain separate.

GreatPoint Ventures Partner Emeritus. His published career includes leading Oracle as president and chief operating officer, followed by fourteen years at Kleiner Perkins. Other company and nonprofit affiliations in his biography are career context rather than separately verified current roles.

GreatPoint Ventures is a San Francisco venture investment firm whose legal investment manager is Greatpoint Investment Management, LLC, CRD 271032. Its strategy spans enterprise software and AI infrastructure, healthcare and life sciences, industrial technology and food technology, combining capital with operating experience. The firm describes a selective, hands-on approach to early-stage investment. Its published portfolio includes healthcare AI platform Qualified Health, imaging-workflow company Sirona Medical, AI research platform Consensus and forecasting infrastructure Nixtla. These published holdings establish its technology and healthcare relevance; directory membership alone does not establish a specific financing round or ticket. The current website names eleven team members, including Ray Lane as Partner Emeritus; DJ Patil is additionally verified as a partner in the manager’s March 2026 Form ADV and current issuer biography, despite not appearing in the website directory. Thirteen legal pooled vehicles are identified in the current Form ADV, comprising main or parallel funds and transaction-specific vehicles. Their unverified final close sizes and dates remain unknown. An historical Fund I Form D reports capital sold rather than an independently confirmed final close. Company founders’ enterprise-value track record, individual LP commitments and regulatory gross asset values are not fund closing amounts. This exact gpv.com manager is distinct from Great Point Partners, the Greenwich healthcare private-equity firm, and from GreatPoint Energy and similarly named brokerages.

The Safe Artificial Intelligence Fund (SAIF) is an early-stage venture fund supporting startups building tools for safer, more secure and responsible AI deployment. It invests in alignment and interpretability, protection of models and agents, governance and compliance, biological and weapon-risk detection, misinformation resilience, model benchmarking and decision-support tools. Founder Geoff Ralston provides hands-on mentorship on product-market fit, go-to-market and fundraising. The fund publishes a USD100,000 startup investment offering; its total fund corpus is undisclosed. This manager is distinct from the unrelated SAIF Partners investment firm and SAIF Autonomy startup.

Tracks technologies and companies addressing societal AI risks across governance, labour, security and public trust. Organises fund events, investment communications and startup discovery.

Leads research into existential and biological risks from advanced AI while managing fund operations and portfolio tools. Previously led product at Academy College Prep.

David S. Wichmann is a Boston Scientific board director, appointed inJune2021. He previously led UnitedHealth Group as chief executive and served in financial and operating leadership roles there, with earlier experience at Arthur Andersen and Advanced Machine Company. He studied accounting at Illinois State University.

Ellen M. Zane is a Boston Scientific board director, appointed inApril2016. She is chief executive emeritus of Tufts Medical Center and founding chair of Tufts Medicine, with earlier hospital-system leadership at Mass General Brigham and Quincy Hospital. She studied audiology and speech-language subjects at George Washington and Catholic University.

Cathy R. Smith is a Boston Scientific board director, appointed inFebruary2026. She is chief financial officer of Starbucks and previously held financial leadership roles at Nordstrom, Bright Health and Target. Her education includes UC Santa Barbara and the University of Southern California.

Cheryl Pegus is a Boston Scientific board director, appointed inMay2024. A cardiologist, she leads FlyteHealth and has earlier strategic-investment, clinical and operating leadership experience at Morgan Health, Walmart, Cambia, Walgreens, Johnson & Johnson, Aetna and Pfizer.

Edward J. Ludwig is a Boston Scientific board director, appointed inMarch2014. He previously led Becton Dickinson as chief executive and board chairman and has finance and medical-technology governance experience. He studied economics and accounting at the College of the Holy Cross and business at Columbia.

Susan E. Morano is a Boston Scientific board director, appointed inJune2023. Her earlier career includes Johnson & Johnson MedTech business development, strategic operations, finance and transaction leadership. She holds degrees from Villanova and Columbia.

David Habiger is a Boston Scientific board director, appointed inJuly2024. He is vice chairman and former chief executive of J.D.Power, with earlier technology-company leadership, venture investing and private-equity advisory experience. He studied at St.Norbert College and the University of Chicago.

James Yu is a healthcare data integration professional publicly associated with Qualified Health. His own profile describes more than twenty years connecting clinical data systems and identifies business studies at the University of North Carolina at Chapel Hill. An indexed self introduction states that he joined Qualified Health as data integration manager following its March2026 financing. His matching profile and company employee listing distinguish him from other software professionals and physicians with the same name. An authentic public portrait was not verified.

Jessica L. Mega is a Boston Scientific board director, appointed inJune2023. A cardiologist and co-founder of Verily, she previously led its medical and scientific work and directed cardiovascular clinical research at Harvard and Brigham & Women’s Hospital. She studied at Stanford, Yale and Harvard.

Melissa Wenk is listed by Qualified Health among its publicly associated employees and confirms joining the team in her own professional post. She describes work with health-system leaders and product launches, as well as earlier experience at the Advisory Board and Kraft Foods. Her precise current job title and authentic public portrait were not independently verified, so no executive seniority or tenure date is invented.

Mike Higgins is listed among associated employees on Qualified Health’s own public company page, linked to the Michael R. Higgins professional profile. A current official biography, precise operating title and authentic public portrait were not accessible in this audit. This identified association is retained with explicit qualifications and is not merged with the similarly named Arizona insurance broker or other unrelated professionals.

Stephan Mabry is the named author of Qualified Health’s September2026 article on data pipelines for healthcare AI. His work discusses clinical-data integration, data semantics, operational freshness and architectures supporting model training, evaluation and inference. His matching professional profile reposts the article as his own work. The publication proves a technical contributor relationship; a precise company employment title and authentic portrait were not independently verified.

Kenneth Stein is senior vice president and global chief medical officer of Boston Scientific, appointed inFebruary2023. He oversees clinical, medical-safety and medical-affairs work and previously served as chief medical officer for rhythm management. He is a cardiac electrophysiologist with earlier Cornell medical faculty experience and degrees from Harvard and NYU.

Stephen Morse is senior vice president and president, Asia Pacific, at Boston Scientific, a role held sinceMay2022. His earlier positions include leading Japan operations and cardiovascular and rhythm-management businesses. He joined the company in1998 after serving in the US Air Force and holds engineering, management and financial-economics degrees.

Jodi Euerle Eddy is senior vice president, Enterprise Services and Digital Officer, at Boston Scientific. She oversees enterprise technology, digital health, artificial intelligence, analytics, cybersecurity and business services. Earlier she held information-systems leadership positions at General Electric. She studied computer science at Southern Connecticut State University.

Rosaleen Burke is senior vice president, Global Quality and Regulatory, at Boston Scientific. She has held this role sinceFebruary2017 and previously directed divisional and international quality activities. She joined the company in1997 and studied biotechnology, microbiology and biochemistry inGalway and business at Oxford Brookes.

Xavier Bertrand is senior vice president and president, Europe, Middle East and Africa, appointedDecember1,2024. His career includes Boston Scientific regional leadership, Medtronic, ATS Medical, Biosensors and managing Symetis before its acquisition. He studied finance at KEDGE Business School.

Charlie Attlan is senior vice president, Strategy and Business Development, at Boston Scientific. His responsibilities include corporate strategy, acquisitions, divestitures, joint ventures, licensing and venture-capital and minority investments. His earlier investment-banking career includes Credit Suisse and BT Alex Brown; he studied economics and mathematics at Princeton.

Paudie O’Connor is executive vice president, Global Operations, overseeing supply chain, quality, regulatory affairs, enterprise services and research operations. His earlier career includes engineering, operations and supply-chain leadership. He studied mechanical engineering at Trinity College Dublin and industrial engineering at University College Dublin.

Miriam O’Sullivan is senior vice president and chief human resources officer of Boston Scientific, appointed inJanuary2025. She directs global people operations, rewards and talent development. Her earlier career includes Boston Scientific manufacturing and supply-chain human resources, IBEC and UCB Pharma; she studied at the University of Limerick.

Jonathan R. Monson is executive vice president and chief financial officer of Boston Scientific, appointed inJune2025. He oversees finance, treasury, tax, audit, investor relations and corporate business development. His previous roles include investor relations, global controller and chief accounting officer; he is a College of the Holy Cross graduate and certified public accountant.

Joseph M. Fitzgerald is executive vice president and group president, Cardiovascular, overseeing global heart therapies and peripheral interventions. His Boston Scientific career includes leadership of cardiology, rhythm management, electrophysiology and neurovascular businesses.

Arthur C. Butcher is executive vice president and group president, MedSurg and Asia Pacific, overseeing businesses including neuromodulation, endoscopy and urology. He joined Boston Scientific in1997 and previously led endoscopy and regional operations. A September2026 SEC disclosure announces retirement from this executive role effectiveJanuary1,2027; that future transition has not occurred as ofOctober7,2026.

Vance R. Brown is executive vice president, general counsel and corporate secretary of Boston Scientific. He leads its legal and compliance functions and previously directed international legal teams, venture-capital transactions, mergers and corporate governance. Earlier he practiced at Skadden; he studied at Western Ontario and Harvard Law School.

DIG Ventures is a European early-stage venture capital firm backing technical founders in B2B software, artificial intelligence and cloud infrastructure at pre-seed and seed. Founded by MuleSoft founder Ross Mason, it draws on founders’ and operators’ experience to help companies turn technical products into commercial businesses. Its support includes early customer acquisition, repeatable sales processes, open-source monetisation, hiring, product strategy, fundraising and expansion into the United States. DIG Ventures Advisors Limited is the firm’s published regulated advisory entity.

Sentinel Global is a San Francisco-based, multi-stage venture capital firm investing worldwide in enterprise technologies built for mission-critical performance, regulatory readiness and adoption across complex systems. Its themes include enterprise AI and cloud infrastructure, cybersecurity, quantum and privacy technologies, programmable financial infrastructure, and AI-enabled supply-chain and industrial operations. The firm combines investment capital with research and introductions to enterprise customers. Its Sentinel Labs platform produces custom analysis and briefings and coordinates an Industrial Advisory Council to help bridge the gap between technology builders and adopters.

Leads finance and administration, bringing fund operations, financial management and reporting experience from Connect Ventures and Kindred Capital.

Previously invested at Radian Capital. Supports companies in strategy, corporate development, go-to-market and navigating complex and regulated markets.

Previously entrepreneur in residence and general manager in Intel’s corporate incubator, where he ran deep-tech ventures. Co-founded and led Consumer Physics, which developed a handheld near-infrared molecular sensor.

Previously a Managing Director at CPP Investments and Partner at Sequoia Capital Global Equities, with growth equity, venture and crossover investment experience. Holds an MBA from Harvard and computer science and management science degrees from Stanford.

Former Managing Director and Co-Head of the Tech Investment Group at GIC, where he built a global venture program. Founded Sentinel Global and its research and adoption platform Sentinel Labs.

A technical researcher with experience in blockchain implementations at Genesis Trading, connecting protocol engineering to practical uses and safety.

Supports regulated technology businesses with international growth, policy and market entry. Previously held leadership roles at Coinbase, Kraken and OKX and senior legal roles at Morgan Stanley.

An early MuleSoft commercial hire in Europe, with experience in sales, customer success and strategy through IPO and acquisition. Helps technical founders build go-to-market functions.

Supports the partnership and office, with administration experience across private equity, consumer goods and venture capital.

Previously invested at Lightspeed, Target Global and Summit Partners. Co-founded YPlan, acquired by Time Out Group, and works with early and growth-stage technology companies.

Runs operations and partnerships across AGI House's events, programs, and enterprise relationships. Cornell alum and member of Global Women in VC. Current affiliation is published by the AGI House platform; guest-speaker lists and personal investments are not automatically manager or individual participation records.

Founder & CEO of FunPlus, a global leader in interactive entertainment with $1B+ annual revenue. Early personal investor in Moonshot AI, xAI, Anthropic, OpenAI, Databricks. Current affiliation is published by the AGI House platform; guest-speaker lists and personal investments are not automatically manager or individual participation records.

Leads AI engineering and research at AGI House, building the platform behind its community, events, and labs. MIT alum, ex-Google, and previous founder. Current affiliation is published by the AGI House platform; guest-speaker lists and personal investments are not automatically manager or individual participation records.

Builds the software and AI systems that power AGI House's platform and programs. Harvard researcher with a background in physics-informed machine learning. Current affiliation is published by the AGI House platform; guest-speaker lists and personal investments are not automatically manager or individual participation records.

Founder of AGI House, with a mission to accelerate humanity's transition to AGI. Passionate about connecting the world's top AI researchers, founders, and enterprise leaders. Current affiliation is published by the AGI House platform; guest-speaker lists and personal investments are not automatically manager or individual participation records.

Founder of Google X (Waymo), Udacity, and Kitty Hawk. Founding Director of Stanford AI Lab. Passionate about AI and autonomous systems. Current affiliation is published by the AGI House platform; guest-speaker lists and personal investments are not automatically manager or individual participation records.

AGI House Ventures is the early-stage artificial-intelligence investment platform associated with Rocky Yu’s AGI House community in Hillsborough, California. The platform combines venture investing, fellowships, founder and researcher gatherings, enterprise introductions and applied AI activity through AGI House Labs. Its official history dates the community launch to 2023. A BlueFocus stock-exchange-filed limited-partner disclosure identifies its fund general partner as AGI House Ventures GP, LLC, a Delaware limited-liability company registered under number 7592070 and formed 27 July 2023, with Rocky Yu leading investment decisions. The related AGI House community and Labs names describe the broader platform; platform staff roles here do not assert employment by the GP legal company. The official venture team names Rocky Yu as general partner, Sebastian Thrun as AGI partner and Andy Zhong as investment partner. Its main public directory additionally names chief technology officer Jesus Lares, operations and partnerships leader Alexa Orent, and technical staff member Marcos Johnson Noya. The investment thesis covers AI-native infrastructure, models, agents, orchestration and intelligent systems for physical-world industries. The published portfolio includes voice and foundation models, developer and compute infrastructure, video generation, AI chip design, numerical computing, robotics, healthcare and neuroscience; Orbit Technology is specifically labelled neuroscience. Own-source portfolio backing is kept separate from guest speakers, community residents, enterprise partners and personal angel investments. The official website describes an early-stage fund making investments up to USD1M; this is a potential company-ticket limit, not fund size or a disclosed check in every portfolio company. AGI House Ventures Fund I, LP is an actual Delaware vehicle. Its SEC Form D reports USD21,105,000 sold to 44 investors, with first sale 1 November 2024 and an indefinite ongoing offering; this is a reported subscription snapshot rather than proof of a final fund close. BlueFocus’s April 2026 disclosure describes a USD1M LP subscription and a fund ceiling of USD50M while fundraising remained ongoing; neither amount replaces exact final closed fund size. Clair Health transaction counsel names AGI House as a participant in the USD11.6M seed announced 17 June 2026; the institutional brand is recorded without pretending the counsel release identifies a specific fund or legal SPV. The Hillsborough agihouse.org platform is distinguished from similarly named San Francisco agihouse.ai and India communities rather than automatically merging them.

Bust is the Stockholm venture investment arm of Harmar, a private family-owned investment company. It invests early in consumer-focused technology businesses and brands, including businesses that connect technology with consumer experiences. Its approach combines long-term equity investment with brand-building support and close work with founders. The firm explicitly operates outside a conventional pooled venture fund structure. Its own portfolio includes consumer companies alongside software and AI investments such as Hypertype.

Partnerinvest Norr is a venture capital investor supporting early-stage and growing companies in Norrbotten and Västerbotten in northern Sweden. It provides minority equity and convertible financing alongside private investors, with active ownership, board participation and help with subsequent funding. Its mandate spans scalable businesses across sectors, including software, industrial technology, life sciences and medical technology. The firm manages regional funds financed through the European Regional Development Fund and regional co-financiers, and is wholly owned by the Norrlandsfonden foundation. Its investment operations began in 2010.

With 10 years of experience in building, growing, and running communities in video games, Alex supports the Makers portfolio with all things community and audience management. After Ubisoft and the start-up studio world, he now helps build scalable strategies befitting the individual projects. As a gamer and self proclaimed "nerd" himself, he loves bringing his insights to help founders build studios with a deep understanding and appreciation of the player.

Originally from Iceland but currently operating on the west coast of North America, Alli engages with founders and supports portfolio companies across America and Europe. Alli spent his previous eighteen years deep in the trenches of PC online game development. He was part of the original team that shipped EVE Online and scaled up production for EVE and across CCP globally. Afterward, he joined Riot Games as the Development Director on League of Legends and later focused on production for Riot's subsequent games.

Andrew partners with founders building innovative products, distribution platforms, and business models in games and interactive entertainment. He has a lifelong curiosity about how technology changes the way people work, play, and build communities. In games, he is especially drawn to how technological shifts are amplified by systems design and storytelling — turning new tools into experiences that entertain, teach, connect people, and help them achieve real-world goals. At Makers, Andrew is a board member and close advisor to a global mix of PC, mobile, AI-first, real-money, and crypto-enabled companies. For new investments, he is especially excited by unconventional approaches to entertainment enabled by emerging technology. Outside work and games, you can find him tinkering with half-baked consumer apps, reading fiction, writing Letterboxd reviews, or spending time in the mountains.

Anna was part of the original business team at Valve that built the Steam platform and led gaming's transition to digital distribution. She spent 6 years leading platform growth, before joining Oculus to run content strategy for the launch of the Rift. Currently, she is the CEO of Bad Robot Games, focusing on the exciting intersection of gaming and linear entertainment. She's also a Venture Partner at Makers Fund, focused on helping portfolio companies across the globe to scale their businesses.

Curtis spends his time finding and supporting founders across Europe and North America. Prior to Makers, Curtis has worked in VC, consulting, and in growth roles at start-ups -focusing on consumer and technology companies. In a past life Curtis played Halo 3 competitively and facilitated sponsorships for some of the earliest eSports creators. He is based out of London but originally from Toronto.

Donovan has spent the last 20 years in the game media space as he built websites, tools, and unique product services for some of the largest game brands in the world. After serving as President of Curse, he spent time as President of Fandom where he helped drive the mission of serving creators at a massive scale. A lifelong gamer and advocate for community, creators, and ugc, Donovan continues to support game developers in his newest venture, publishing games. As an avid and lifelong gamer, Donovan plays a variety of games but mostly enjoys grand strategy and city-builder style games.

Garry brings over 20 years of experience scaling companies across many genres including, Games, B2B Platforms, Media and Web3. Garry enjoys providing tailored advice and support to individuals and companies of all stages and sizes. He engages with our founders across the globe to advise them on all thing’s talent. As a lifelong gamer, he is passionate about helping our founders build their companies with the world’s best talent.

Greg has been an avid gamer since he was 6 years old and is especially passionate about the medium’s ability to bring people together and tell unique stories. Before joining Makers, he invested out of SoftBank’s Vision Fund, leading over $1B of transaction volume across Web 3.0, consumer technology, and gaming assets. He started his career as a management consultant at McKinsey & Company, focusing on TMT strategy and Private Equity.

Jay has worked in interactive entertainment for the last sixteen years as an industry advisor, focusing on helping early stage and large international firms with their strategies, investments and growth, working globally across Asia, North America, and Europe. A lifelong gamer and advocate for the industry, his passion is in supporting individuals and companies—large or small—who make positive contributions to the rapid growth of interactive entertainment.

Jiang focuses on finding and working with founders as well as strategics in Asia and Americas. She’s a passionate gamer, especially excited about the intersection of tech and storytelling, and an amateur creator in multiple forms incl. writing, theater, movies and music. Prior to joining Makers Fund, she worked with consumer and tech companies across US and Asia helping them on strategy, growth and investing.

Joost is considered “the top academic in the $160 billion video games industry.” He teaches at the NYU Stern School of Business and is the author of One Up: Creativity, Competition, and the Global Business of Video Games. Previously, Joost was co-founder and CEO of SuperData Research, a games market research firm acquired by Nielsen in 2018. He publishes a weekly newsletter on gaming, tech, and entertainment called SuperJoost Playlist.

Lia is a New York-based Growth operator partnering with founders and creators in the UGC space. Prior to working with Makers, she spent five years in early and growth-stage venture capital at Stripes and Primary Ventures, leading investments across consumer and fintech. A lifelong gamer, Lia's entrepreneurial journey began with selling custom user lookups on Neopets and hair mods for The Sims 2.

Michael has spent the last 15 years helping companies grow and scale overseas in the interactive entertainment and consumer industries. He works with founders building mobile experiences and platforms and is passionate in building high performing partnerships between product and go to market teams. An engineer at heart, he was a Senior Product Director at Tencent and prior to that a Data Scientist working with companies in the entertainment and consumer industries. In his earlier years, he cut his teeth in esports as a competitive Counter Strike player.

Nathaniel supports the Makers portfolio in branding, go to market strategy, and key hiring decisions across marketing disciplines. His background includes marketing, communications, and oddly, systems design across Gearbox Publishing and Riot Games. He writes a postcard to his mom wherever he goes and frequently imagines how much more he could get done if Pikmin were real. Nathaniel's natural homes are strategy titles, anything Nintendo, and any game that washes away real life with its immersive world.

Ryann has spent the past decade partnering with interactive entertainment companies — from PC/console studios to developer tools and virtual sandboxes. He has a particular passion for working with next-generation creators from unconventional backgrounds who are redefining how games are built and experienced. He’s known for his long-term approach to founder support, and ability to navigate both breakout growth and more complex, less visible moments. Ryann oversees Makers Fund’s investment and portfolio efforts in the Americas and splits his time between the U.S. West Coast and Asia. Ryann Lai is a Makers Fund investor named as a director of TribeVR Inc., the legal entity trading as Ramen VR, in its 2021 and 2022 SEC Form D filings. The historical director role does not establish a current Ramen board seat or a personal equity check. His genuine named portrait is published on Makers Fund’s own team page.

Tyler spends his time investing in and supporting founders across North America. Prior to Makers, Tyler advised clients across industries on corporate strategy as well as creating, launching, and operating new technology products. A lifelong gamer, Tyler has a passion for all genres but is known to be a horror evangelist. Away from his controller, he is also an avid moviegoer and loves spending time outdoors.

Walter invests in and supports founders across Europe, the Middle East, and India, specializing in mobile free-to-play and PC/console premium studios and publishers. Prior to Makers Fund, he worked at Epic Games, where he shaped strategy for Fortnite Battle Royale and UEFN. He is based in London and originally from Italy. Outside work, Walter enjoys a diverse array of games, but in particular story-driven RPGs and souls-likes.

Yoyo focuses on investing in and supporting founders across Asia. She has a passion for otome and party games, as well as K-pop and anime.  Before joining Makers, Yoyo led investments in gaming and consumer tech companies based in Japan and supported overseas teams with their market expansion efforts.

Leads Innovation Fund and telehealth communications at CHCF. Previously held communications and public-engagement roles at Interact Communications, California State University Long Beach and healthcare safety-net organizations. Holds Harvard and UC Berkeley journalism qualifications.

Brydge Club is a women-focused angel investing collective, syndicate platform and educational community founded by Ruffin Mitchener. Its current website publishes actual co-investments in Clair Health, Bumo, GOB, Lore, Offe Market and POCA, alongside venture firms including a16z, Khosla Ventures, Offline Ventures, True Ventures, Baukunst, Village Global and Precursor. Relevant technology backing includes Clair Health’s investigational hormone-monitoring wearable and Bumo’s family assistant. Members choose investments deal by deal: the club says it has no annual investment commitment, offers access to opportunities with minimum checks as low as USD1K, and reports a per-check range of USD1K–50K. These are access policies rather than proved company tickets. Its published USD500K+ deployed to date is an aggregate deployment claim, not a closed fund size or additional cash financing round. The website reports200 members; its founder’s larger media audience is distinct from this investing membership. Ruffin is the only independently verified publicly named operating leader. Community members, workshop speakers and podcast guests are not assumed to be employees or institutional buyers. No public legal manager suffix, specific deal SPV, committed fund vehicle or fund closing has been verified. The podcast dates to2022 and the founder announced the private community launch during2024; a single legal founding date is not assumed.

CHCF Innovation Fund adviser with Kaiser Permanente and The Permanente Federation operating experience. The CHCF directory contains differing external titles; only the foundation advisory affiliation is recorded as a role.

Healthcare-services and software investor serving as CHCF Innovation Fund adviser. CHCF identifies his Health Velocity Capital affiliation and a healthcare investment career beginning in1992.

Ruffin Mitchener is the founder and creator of Brydge Club, an angel investing community, syndicate platform and media brand. Her own instructor biography describes personal angel investing and leading syndicate opportunities for the club’s women investors. She previously worked at Deloitte and as an operator at a consumer fintech startup, and holds an MBA from UCLA Anderson. Her personal investments, community members’ checks and the collective’s investments are distinct attributions.

CHCF Innovation Fund adviser and healthcare venture investor associated with Polaris Partners in the fund’s own directory. External fund assets are not CHCF fund commitments. Polaris managing partner in San Francisco, focused on healthcare. Joined as an associate shortly after the firm’s1996 founding. The current biography names work with Ajax Health, Neumora, Nomad Health and Sovato.

CHCF Innovation Fund adviser with a healthcare venture-investment background at Maverick Ventures. The fund directory publishes his manager affiliation and selected company board work; those external roles are not automatically treated as currently verified appointments.

Provides CHCF Innovation Fund program support. Previously coordinated administrative support at Telecare Corporation across finance, human resources and information technology. Holds Sonoma State business-administration and marketing qualifications.

Leads communications supporting CHCF Innovation Fund and CalAIM. Previously a health journalist for25years, including KQED, with work published by NPR, Kaiser Health News and JAMA Internal Medicine. Holds a Brown economics degree.

Invests in mission-aligned early- and growth-stage health companies. Previously an investment manager at Acumen America, working across healthcare, financial services and workforce development, and on its Medicaid Innovation Collaborative. Holds Santa Clara accounting and information-systems qualifications.

Directs CHCF Innovation Fund investments and portfolio support. Previously worked in strategy consulting, McKinsey and J.P. Morgan healthcare investment banking. Holds Stanford human-biology and Harvard public-policy qualifications.

Hanneke Smits serves on Wellcome’s investment committee, appointed in2025 for a three-year term. Her investment career spans private and public markets, including chief investment officer of Adams Street Partners, CEO of Newton Investment Management and global head of BNY Investments. The Van Leer Foundation’s own biography describes those BNY roles as previous positions. She holds a BBA from Nijenrode University and an MBA from London Business School, and has led industry initiatives including Level20 and the30%Club.

John-Arne Røttingen is chief executive officer of Wellcome, having joined inJanuary2024, and a member of its investment committee. He leads the charitable foundation’s science and health mission. His investment committee role is a foundation governance affiliation rather than a commercial venture fund management position.

Girish Reddy is an external member of Wellcome’s investment committee. He founded and led hedge fund investment manager Prisma Capital Partners after a Goldman Sachs career in equity derivatives, where he became a partner. He earned an electrical engineering degree from IIT Madras and engineering and MBA degrees from Cornell. His university’s original alumni biography and portrait establish his identity; historic firm asset figures are not current Wellcome fund commitments.

Sandra Robertson serves on Wellcome’s investment committee, appointed in2025 for a three-year term. She founded Oxford University Endowment Management as its CEO and CIO in2007 following14years at Wellcome, latterly as co-head of portfolio management. OUem’s December2025 announcement confirms that Neamul Mohsin succeeded her as CIO inJanuary2025, while she continues as CEO with retirement planned for the end of2026. Older university biographies calling her current CIO are historical.

Diana Noble is a Wellcome governor and investment committee member. She joined the Board of Governors on6November2023. She founded private equity leadership adviser Kirkos Partners and served as CEO of the UK development finance institution CDC from2011 to2017. Earlier she led international operations and treatment-access programmes at the Clinton Health Access Initiative. Her current governance work includes deputy chair of the Bank of England’s Court of Directors.

Cressida Hogg is an external member of Wellcome’s investment committee and an infrastructure and private equity investment leader. She helped establish3i’s infrastructure business and became its managing partner, then led infrastructure investing at the Canada Pension Plan Investment Board from2014 to2018. She chairs BAE Systems and serves as senior independent director of London Stock Exchange Group. These outside positions do not imply employment in Wellcome’s investment division.

Martin Halusa is an external member of Wellcome’s investment committee. He founded Apax Partners’ German platform in1990 and later served as the global firm’s CEO and chairman; those executive offices are historical rather than current Wellcome employment. Earlier roles included president of Swarovski America. The London School of Architecture’s own biography records degrees from Georgetown University, Harvard Business School and the University of Innsbruck. He is distinct from the similarly named German corporate communications executive.

Julia Gillard chairs Wellcome’s Board of Governors and serves on its investment committee. She joined the board on12April2021. She was Australia’s deputy prime minister and first woman prime minister between2007 and2013, and later chaired the Global Partnership for Education. Her health and education governance work includes Beyond Blue and the Global Institute for Women’s Leadership at King’s College London.

Maggy Chan is chief operating officer of Wellcome and a member of its investment committee. She joined as COO inJanuary2025. Her responsibilities cover finance, risk, digital and technology, legal, sustainability and people, supporting the charitable foundation’s operations. The published committee affiliation describes oversight of the endowment investment platform rather than a separate commercial fund partner position.

Tracy Blackwell is an external member of Wellcome’s investment committee. She helped establish Pension Insurance Corporation in2006 and served as its chief investment officer before becoming CEO in2015. PIC’s2025 annual report confirms that she retired as CEO and from the PIC and PICG boards on31December2025; older biographies describing her as current PIC CEO are historical. Her continuing Wellcome committee membership is confirmed by its current public roster.

Richard Gillingwater chairs Wellcome’s investment committee and is a governor of the foundation, appointed to the board on1September2019. His career has included establishing and leading UK Government Investments, chairing the UK development finance institution CDC, serving as dean of Cass Business School and chairing the Open University. His Wellcome affiliation is a governance appointment rather than a claim that he is an investment division employee.

Robert Holl, CFA, is a principal in Wellcome’s investment division. He joined in2012 after qualifying as a chartered accountant at Deloitte. His2024 Oxford Real Estate Society biography identifies responsibility for commercial property investments across direct and indirect assets, including life sciences, student accommodation, hotels and strategic land in public and private markets. The current official Wellcome roster confirms his principal title, and the Wellcome Genome Campus names him on its science and technology advisory group.

Elaina Elzinga, CFA, is a principal in Wellcome’s investments division, overseeing its absolute return and climate strategies. She manages hedge fund and other investments intended to provide low equity-market exposure and uncorrelated returns, and leads investment stewardship and net-zero work. She joined Wellcome in2010 after investment banking and investment management roles at Goldman Sachs. She studied history at Newnham College, Cambridge, and serves on the Cambridge University Endowment Trust board.

Geoffrey Love is a principal in Wellcome’s in-house investment division. He joined in1998. The foundation’s2019 biography described responsibility for venture capital funds, equity long/short hedge funds and direct private and public company stakes. He holds an economics degree from the University of Edinburgh and has served on the Marie Curie investment committee. Wellcome’s current roster confirms his continuing principal affiliation; older responsibility and outside committee descriptions are historical.

Robert Coke is a principal in Wellcome’s in-house investment division. He joined in1999 after training in emerging-market fund management. Wellcome’s original2019 biography described his team’s private equity and residential property investments and his work across emerging-market and industrial-sector investments. He holds an economics degree from the University of Exeter. The current official roster confirms his continuing principal title; older detailed investment responsibilities are identified as historical.

Pragati Dwivedi contributes public product and customer stories for New Lantern and lists the company as her current professional affiliation. She authored its September 2026 worklist seminar and radiology customer articles. Her self-published profile lists University of Toronto Mississauga education; her exact company job title and appointment date are not public.

Rinko Ghosh is listed among AxoNeural’s board directors. Its external-employer caption identifies him as President and CEO of IHP Therapeutics, corroborated by IHP’s own team directory; he is not represented as AxoNeural CEO. A longer AxoNeural director biography is not published in the reviewed team page.

Elizabeth Sump is listed on AxoNeural’s board. Its biography describes technology-development and strategic-alliance work at Cleveland Clinic, including startup formation, regulatory planning and research consortia; it also identifies earlier health-policy and Armed Forces Institute of Regenerative Medicine commercialization work. She holds an Ohio State University BS. The external Clinic Senior Director caption is published by AxoNeural and not assumed to be a current executive role at AxoNeural.

Vidhya Gopalakrishnan, PhD is an AxoNeural director. Its biography describes pharmaceutical development and operations through clinical development and regulatory submission, including earlier Retrotope, Quark Pharmaceuticals, Neuraltus, Jazz, Aerogen, ALZA and Cygnus roles. She earned a chemistry master’s at IIT Madras and a PhD at National Chemical Laboratory, Pune. The BioJiva COO caption identifies an external employer role, not AxoNeural COO.

Michael P. Steinmetz is AxoNeural’s medical adviser. Its biography identifies his Cleveland Clinic neurosurgery chair and Case Western Reserve neurological-surgery teaching roles, with clinical and research interests in complex and minimally invasive spine surgery, trauma and spinal cord injury. He trained at Texas Tech, the University of New Mexico, Cleveland Clinic and the University of Wisconsin.

Vinod D. Labhasetwar founded AxoNeural Therapeutics and serves as Consulting CSO according to its public team directory. He is a Cleveland Clinic professor and endowed chair of nanomedicine whose research spans nanoparticle drug delivery and antioxidant enzyme formulations. His work includes Neupron for neurological injury; NIH lists him as contact principal investigator for AxoNeural’s2021 STTR grant.

AxoNeural Therapeutics, Inc. is a Cleveland, Ohio preclinical biotechnology company founded in2020 as a Cleveland Clinic spinout. It develops nanoparticle-delivered therapeutics for neurological injuries and neurodegenerative diseases. Its lead Neupron program encapsulates antioxidant enzymes in polymeric nanoparticles to counter oxidative injury, reduce secondary degeneration and support recovery after acute spinal cord injury. Published animal-model findings and formulation-development work underpin the program; the reviewed sources do not establish clinical efficacy, marketing approval or a completed human efficacy trial. Its public directory names founder and Consulting CSO Vinod Labhasetwar, medical adviser Michael Steinmetz and three board directors: Elizabeth Sump, Vidhya Gopalakrishnan and Rinko Ghosh. The external employer titles shown beneath board members identify Cleveland Clinic Innovations, BioJiva and IHP Therapeutics roles rather than AxoNeural executive appointments. Cleveland Clinic Ventures backing is explicitly published, but no exact equity round, ticket, lead or cash-close date is disclosed. NIH awarded the company USD399,987 for PhaseI STTR project1R41NS122587-01 in May2021; Ohio Third Frontier approved a USD198,000 technology-validation and commercialization grant in July2024. These are non-equity grant awards rather than venture financing or confirmed grant disbursements. NIH and Department of Defense support for originating research is acknowledged, but institutional laboratory grants are not assumed to be additional company financing. It is distinct from Axo Neurotech and AxoProtego Therapeutics.

Adin Hodovic is a platform engineer at New Lantern, building and operating cloud infrastructure for its medical-imaging software. His own current résumé describes Kubernetes, infrastructure as code, CI/CD, observability and production reliability. He returned to New Lantern on July 1, 2026 after a site-reliability role at AuthZed; his earlier part-time software-development role at New Lantern ran from August 2021 to March 2022.

Aaron Jones publicly lists New Lantern as his current affiliation. His own biography describes over 25 years of network and security engineering experience, including network infrastructure and security certifications. His exact formal employer title is not exposed in the accessible primary profile.

Alec Huang publicly lists New Lantern as his current professional affiliation and Washington University in St. Louis education. His profile also identifies a phage-genome annotation publication. His precise New Lantern role and exact appointment date are not exposed in the accessible primary source.

Bruno Alves de Faria publicly identifies New Lantern as his current affiliation. His own professional biography describes an information-systems education and software-architecture specialization. His exact current employer title is not exposed in the accessible primary profile.

Kevin Dietz is a New Lantern team member with healthcare technology and technical customer-support experience. His own profile lists Arizona State University education with summa cum laude distinction and describes prior customer-facing healthcare technology work at Lexmark. His exact current title is not visible.

Nathan Gugel publicly lists New Lantern as his current affiliation and describes himself as a Stanford computer-science graduate. His self-published profile describes software work at FullStory and a student haptic-headset project supporting people with visual impairments. His precise current New Lantern job title is not public.

Ruxandra Stanciu publicly describes being part of the New Lantern team building its AI radiology workflow solution. Her own posts discuss its agentic worklist and imaging functionality. Her exact formal job title and appointment date are not publicly disclosed in the accessible primary source.

Jennifer Starling is a New Lantern team member with a nursing and healthcare-information background. Her own profile describes joining the company and lists registered-nurse and HL7 CDA credentials, along with project-management and scrum training. Her precise current employer title is not public in the accessible profile.

Jonathan Bowley is a New Lantern team member and a health-information technology professional. His own profile describes extensive experience and multilingual work, and his public posts discuss the company’s worklist and imaging deployments. His exact current formal title is not exposed in the accessible primary profile.

Pranav Kalicheti is a New Lantern team member with a background in quantitative and computational problems. His own profile lists University of Pennsylvania studies from 2016 to 2020 and software projects involving networks, compilers and Android applications. His exact current title is not exposed.

Rohan Kohli publicly lists New Lantern as his current affiliation and recruits engineers for its on-site San Francisco healthcare technology team. His public posts discuss frontend, backend, AI, WebGL and medical-imaging skills; an exact formal employer title is not exposed.

California Health Care Foundation (CHCF) is an independent California nonprofit philanthropy working to improve access, affordability and equity in health care, particularly for people with low incomes served by Medi-Cal. Its CHCF Innovation Fund, formerly styled Health Innovation Fund, is an internal mission-investment program operating since2010, rather than a separately raised outside-LP venture partnership. It invests in early- through growth-stage health-services and information-technology companies and currently focuses on artificial intelligence for safety-net health care. Program-related investments can be loans with warrant coverage or equity investments; their primary objective is charitable impact, with repayments and exits recycled into mission activities. Investments and grants are distinct, and adoption grants may go to providers rather than portfolio companies. Own reporting describes overUSD30M committed to40companies cumulatively; that figure is not a fund closing or verified paid cash. Qualified Health received a specifically disclosedUSD500,000 PRI inMarch2025. The linked investor represents the foundation through its internal Innovation Fund; no duplicate parent or unit investor is created.

Varsha Rao is a healthcare and technology operator, angel investor and published Flare Capital executive partner. Her current manager biography describes previous leadership at Nurx, Clover Health and Airbnb, as well as founding Eve.com. She studied at the University of Pennsylvania and Harvard Business School. SignalFire’s own January2025 investment announcement names her as an actual Qualified Health angel participant. Nurx is treated as a previous employer, despite older personal-site biographies retaining its CEO title. Her authentic portrait comes from Flare Capital’s own named profile.

Nestwell, operated by Go Nestwell Inc. in Santa Monica, California, is a digital environmental-health platform helping households assess and improve exposures in their homes. Its Nestwell Score combines address and property information with percentile-based environmental metrics, nearby hazard sites and live geospatial alerts from public data sources. Customers can order kits for certified partner-laboratory testing of water, air, dust, soil, radon and mold, view measured results and prioritized guidance, and find filters, purifiers and other remediation products. The company’s science framework concerns the exposome and respiratory, developmental and broader environmental health; its reports screen home exposures and are not medical diagnoses. Its privacy policy describes AI-powered chat and backend AI service providers, while its published score methodology is percentile-based. Founder and CEO Ben Parens reported an oversubscribed pre-seed financing closed February2,2026, with the amount and buyers undisclosed. Nestwell later acquired Dwelling Health, a Healthworx Studio venture, and appointed Shiv Gaglani as a strategic advisor. Healthworx Studio lists Nestwell among companies that acquired studio-created assets. Treehub by AI Health Fund separately names Nestwell as a first-check investment; exact allocation and funding-round assignment are unpublished.

Ben Parens is the founder and chief executive officer of Nestwell, a home environmental-health platform. He builds tools that combine location-based exposure information with laboratory testing and practical steps for improving a home’s air, water and other environmental conditions. His own writing describes an oversubscribed pre-seed financing closed on February2,2026, and the work leading to the platform’s 2026 launch. The company subsequently acquired Dwelling Health to expand its clinical scoring capabilities and connections to the healthcare payer ecosystem.

Lauren Eggert is a medical advisor to Nestwell. Its current directory identifies her as an associate professor of medicine at UCSF in pulmonary, critical care, allergy and sleep medicine. Her advisory perspective concerns respiratory health and the effects of indoor and outdoor air pollution. The affiliation is advisory rather than an assumed employment role at Nestwell.

Malathi Srinivasan is a medical advisor to Nestwell. Its current public directory identifies her as a clinical professor of medicine in primary care and population health at Stanford University. She advises on the connection between home environments and health, including environmental considerations for early childhood development and vulnerable adults. This advisory affiliation is distinct from staff employment by Nestwell.

Mark Cullen is a medical advisor to Nestwell. Its current directory identifies him as the former senior associate dean for research and founding director of the Stanford Center for Population Sciences. He brings experience studying the health effects of environmental exposures and emphasizes safe living environments as a factor in long-term health. His university background does not establish a new executive appointment at Nestwell.

Matthew Trowbridge is a medical advisor to Nestwell. Its current directory describes him as a physician and built-environment health expert, founder of Health Intent Partners and former chief medical officer of the International WELL Building Institute. His work focuses on how the design and operation of buildings affect human health.

Shiv Gaglani, MD, MBA, is a strategic advisor to Nestwell, appointed in its announcement of the acquisition of Dwelling Health. He helped develop Dwelling’s home-health platform and co-founded Osmosis, a digital medical-education company acquired by Elsevier in2021. Harvard’s published alumni profile describes his engineering coursework and business-school education. The Nestwell affiliation is advisory and does not establish a new executive job or a personal cash investment.

Beth Siron publicly lists New Lantern as her current professional affiliation. The company’s own public LinkedIn directory also identifies her among its employees. Her exact current job title is not visible in the accessible primary profile.

Chris Tann is publicly identified by New Lantern among the executives discussing its all-in-one radiology workflow platform. His own demonstrations describe the company’s imaging and reporting features. His exact executive job title is not disclosed by the accessible primary company announcement.

Ibrahim Mohamed is a principal engineer at New Lantern, working on medical-image viewing, web infrastructure and AI software. His own portfolio describes responsibility for viewer engineering, mammography and PET imaging workflows. The company names him as Principal Engineer in its public events programme.

Kevin Shen publicly lists New Lantern as his current professional affiliation and Massachusetts Institute of Technology education from 2015 to 2019. His accessible primary profile does not disclose an exact current job title; no specific engineering or management title is inferred from third-party directories.

Ryan Chen is Head of Operations at New Lantern. He leads radiology client deployments and works across engineering, product and clinical teams. He presented intelligent worklist routing at the 2026 SIIM Annual Meeting.

Samir Mehta is publicly identified by New Lantern among the executives discussing its all-in-one radiology workflow platform. This identity concerns the New Lantern radiology professional, rather than unrelated executives with the same name. The accessible primary company announcement does not disclose his exact formal title.

Stephen Woodrow works on engineering and team development at New Lantern. His own recruiting announcements describe scaling the product and infrastructure and hiring experienced backend and infrastructure engineers. His self-published profile lists Massachusetts Institute of Technology education. The engineering-leader title describes these published responsibilities; his exact formal employer title is not exposed in the accessible primary profile.

Shiva Suri is the founder and chief executive officer of New Lantern. He developed its AI-native radiology workflow platform after watching his mother work through fragmented imaging and reporting software. He leads the company’s product and operating strategy.

Swiss presenter, mental coach and public-awareness advocate. The Guido Fluri Foundation’s 2010–2017 publication identifies her as its brain-tumour awareness ambassador. Her own current website verifies her identity and provides an authentic portrait; continuing foundation affiliation is unverified and no clinical or medical-advisor appointment is inferred.

Former member of the Guido Fluri Foundation’s board. The foundation’s older imprint still names her, but the official Swiss Gazette notice published 1 September 2026 records her withdrawal and extinguished signing authority. Exact effective departure day and a reliably matching portrait are not publicly established.

External media officer for the Guido Fluri Foundation through Branson Kirk, where the current agency directory identifies him as managing director and owner. His foundation contact role is recorded without inferring foundation employment or a personal venture-investment check.

Swiss historian and author who led the Guido Fluri Foundation-supported Kinderheime Schweiz historical research project. His own curriculum dates building the project website and recording interviews with formerly institutionalised people to 2010–2014. This published project affiliation is historical, not an assertion of current foundation employment.

Swiss social educator, former KESCHA leader and Guido Fluri Foundation board member. The foundation’s own account and the Our Faces – Our Stories project describe his work in residential youth support, foster-family care and integration assistance for young adults leaving care. This is the social educator associated with the foundation, distinct from the Swiss politician and attorney Bruno Frick.

Swiss entrepreneur, philanthropist and founder of the Guido Fluri Foundation established in 2010. Leads its work on child protection, schizophrenia support and rare brain-tumour research and patient information. His foundation, rather than an inferred personal check, is explicitly identified as machineMD’s 2022 seed lead investor.

Vice-president of the Guido Fluri Foundation’s board, appointed in the December 2024 Swiss Gazette notice under legal name Tânia Maria Fluri-Gomes de Brito Simão. Her own professional profile reports a University of St Gallen doctorate focused on communication for industrial solution providers. Her published foundation work includes the December 2024 Council of Europe conference on child-protection accountability and safeguarding.

The Guido Fluri Foundation is a self-financed Swiss philanthropic foundation established by entrepreneur Guido Fluri in 2010. Its registered legal name is Guido Fluri-Stiftung, UID CHE-115.861.632, with its registered office in Cham, Canton Zug and federal foundation supervision. Its own history dates its establishment to 21 July 2010. It pursues three related purposes: helping children grow up without violence, supporting the social participation of people with schizophrenia and their family caregivers, and improving access to information, research and treatment for people with rare brain tumours, particularly acoustic neuroma. Activities include patient information and self-help through the acoustic-neuroma community, financial support for neurological research and patient care, the KESCHA advice service, the Living with Schizophrenia initiative, child-protection reporting services, historical research into institutional care, the Mümliswil memorial and the European Justice Initiative. The foundation states that it finances its projects without external fundraising; no public exact endowment, assets-under-management figure or closed LP fund is inferred. Its neuroscience and deep-technology investment relevance is concrete: machineMD explicitly identifies the foundation as lead investor in its CHF3.2M seed financing announced 6 September 2022 for AI- and virtual-reality-assisted neuro-ophthalmological diagnostics. This is an institutional foundation investment, distinct from an individual Guido Fluri check, a foundation research grant or the conversion of machineMD’s earlier financing. Current legal leadership comprises founder and president Guido Fluri, vice-president Tânia Fluri-Simão and board member Bruno Frick, the social educator and former KESCHA leader. Official Swiss Gazette notices appoint Tânia in December 2024 and remove Antonia Bissig in September 2026, overriding the foundation website’s older imprint. Nik Schwab is the external media officer through Branson Kirk. Published earlier affiliations of Antonia Bissig, historian Thomas Huonker and brain-tumour ambassador Tanja Gutmann are qualified historically. The foundation is recorded as a nonprofit organization with an Investor identity for its documented company investment, rather than as a commercial venture-capital fund manager.

Navid Farzad is a Frist Cressey Ventures managing partner published in Qualified Health’s investor and adviser roster. His earlier work includes Morgan Noble Healthcare Partners, Enhanced Healthcare Partners and healthcare investment banking and advisory roles. His background spans care-delivery investment and company boards. The Qualified relationship is an institutional/advisory affiliation, not a demonstrated personal investment.

Rose Maher is Qualified Health’s vice president of AI transformation, as identified in its September2026 University of Rochester case study. Earlier company material described her as an engagement manager supporting health-system customers. Her work combines healthcare product management, analytics and implementation. The company’s own staff introduction identifies prior roles at The Health Management Academy and Brightfield. Her authentic named portraitcard is published by the company.

Ian Chiang is a Flare Capital Partners partner listed in Qualified Health’s investor and adviser roster. His background includes healthcare company formation, population-health services at CareAllies and consulting at McKinsey. His published investment work includes clinical-care and healthcare AI companies. He studied biological engineering at Cornell and business at Harvard. The institutional relationship is distinguished from a personal check.

Simon Wu is a Cathay Innovation partner published in Qualified Health’s investor and adviser roster. His work focuses on United States software, financial technology, consumer and digital-health investments. He previously worked at VMware and UBS and studied at Berkeley. Representation of Cathay is not treated as a personal investment or company executive appointment.

Bill Veghte is a technology executive and Athene Partners founder published among Qualified Health’s investors and advisers. His background covers software products, operations and enterprise growth across companies including Microsoft and Hewlett Packard. SignalFire’s own January2025 investment article explicitly names him as a participating angel, separate from his advisory affiliation. His individual ticket size remains undisclosed.

Patrick Conway is a physician and healthcare executive published among Qualified Health’s advisers. His biography describes Optum leadership, prior executive work at Blue Cross and Blue Shield of North Carolina, and senior roles at CMS and its innovation center. He trained in pediatrics and clinical epidemiology. Published outside employer responsibilities are not converted into company staff or personal investment records.

Matthew Lungren is a physician and clinical machine-learning researcher listed as a Qualified Health adviser. His work spans healthcare AI at Microsoft, Stanford and Amazon Web Services. The company’s live homepage identifies a current Office of the CTO role, while an older expanded biography still calls him Microsoft Health and Life Sciences chief scientific officer. The discrepancy is qualified; neither title is represented as a Qualified Health executive position.

Eric Larsen is a healthcare strategist and adviser published in Qualified Health’s investor and adviser roster. His career includes leadership at the Advisory Board Company and work on health-system partnerships following its Optum acquisition. The company’s materials also identify venture-investing and board experience. Differing historical institutional titles are retained as published context rather than asserted as current employer appointments.

Jared Kesselheim is a managing partner at Transformation Capital with experience in clinical medicine and healthcare technology investing. Qualified Health publishes him among its investors and advisers. He previously invested at Bain Capital Ventures and trained as a physician at Massachusetts General Hospital. His published biography describes medical, business and undergraduate education at Harvard. No personal check is inferred from institutional affiliation.

Mohamad Makhzoumi is NEA’s co-CEO and managing general partner and is published in Qualified Health’s investor and adviser roster. He has spent more than two decades investing in healthcare technology and services at NEA, following roles at Summit Partners and UBS. Qualified Health’s July2026 SEC filing explicitly identifies him as a statutory director.

DJ Patil is a GreatPoint Ventures general partner listed in Qualified Health’s investor and adviser roster. He was the first United States chief data scientist and previously served as Devoted Health’s chief technology officer. His background includes data-science leadership at LinkedIn and RelateIQ, as well as public-sector initiatives. His affiliation is not evidence of a personal cash ticket or an executive role at Qualified Health. GreatPoint Ventures’ legal manager also names Dhanurjay A. S. Patil as a partner in its March 24, 2026 annual Form ADV. He is not listed in the eleven-person website directory; current partner status is supported separately rather than inferred from directory absence. The filing gives January 2023 for partner status without an exact day.

Amir Dan Rubin is Healthier Capital’s founding managing partner and CEO. Qualified Health lists him in its investor and adviser roster. His previous executive roles include One Medical, Stanford Health Care and Optum, with experience in care delivery and healthcare technology. His company biography identifies business and health-services education at Michigan and undergraduate study at Berkeley. No personal investment ticket is inferred from his institutional representation.

Beau Norgeot is co-founder and chief AI officer at Qualified Health. He previously worked on AI products at Elevance Health and clinical AI at Lucid Lane. His doctorate at UCSF combined machine learning and personalized medicine, including methods for protecting identifiable information in clinical notes. He writes the company’s articles on applied AI and platform engineering.

Shantanu Phatakwala is a Qualified Health co-founder and chief commercial officer. His background combines healthcare operations, data science and entrepreneurship. He previously served as Haven’s chief data science officer and helped build Evolent Health and Resolution Health. His published biography describes engineering education and machine-learning training at Stanford.

Kedar Mate is co-founder and chief medical officer at Qualified Health. He previously led the Institute for Healthcare Improvement and has a faculty affiliation with Weill Cornell Medicine. His career includes clinical leadership, international health work and healthcare quality improvement. He contributes clinical expertise to the company’s AI deployment and governance work.

Qualified Health PBC is a Delaware public benefit corporation building enterprise AI infrastructure for health systems. Its healthcare-focused platform connects clinical and operational data, enables AI agents and workflow tools, and provides evaluation, governance, access controls and ongoing monitoring. It supports clinical, administrative and financial use cases and works with health systems including the University of Texas, University of Rochester, Emory and Jefferson. The company’s current leadership includes Justin Norden, Kedar Mate, Shantanu Phatakwala and Beau Norgeot; it separately publishes an investor/adviser roster, which is distinguished from employees and statutory directors. SEC records establish incorporation in2023 and its San Carlos principal office, despite differing public summaries of founding year. January2025 issuer and transaction-counsel disclosures describe USD30M early seed funding; later reports split that capital across2024 seed and SeriesA, so no duplicate earlier rounds are asserted. March2026 SeriesB was USD125M. A separate July2026 SEC offering had USD9,999,972 actually sold, below its target, with unnamed buyer and unverified stage. California Health Care Foundation separately documents a USD500,000 program-related investment inMarch2025; that is not automatically VC equity or a grant.

Justin Norden is Qualified Health’s co-founder and chief executive. A physician and AI entrepreneur, he previously founded Trustworthy AI, acquired by Waymo, and invested at GSR Ventures. His published biography identifies a Stanford Medicine teaching affiliation and qualifications in medicine, business, computational biology and computer science. The July2026 SEC filing also identifies him as a director.

Lynx Financial is a Shanghai-based healthcare and life-science investment and financial-advisory firm operating under the Chinese brand 德石资本. It invests in therapeutics and medical technologies and helps companies connect with financial and strategic partners across China and international markets. Its advisory work includes cross-border licensing, mergers and acquisitions, private placements and IPOs. Its own site documents investments and partnerships in companies including Aurealis Therapeutics and Bone Index; Marginum’s issuer announcement confirms Lynx as a new investor in its 2025 pre-Series A financing. The business combines capital investment with transaction advice, so an advisory mandate is not automatically treated as an investment.

Superhero Capital is a Helsinki-based venture-capital fund manager founded in 2015, backing seed-stage, software-driven companies primarily in Finland and the Baltic countries. It initially invests up to EUR 1 million and occasionally backs companies outside this region. Its partners support founders with financing, portfolio development, technology and team evaluation, strategy and business growth. The partner-owned firm manages Finnish limited-partnership venture funds and is registered as an alternative investment fund manager and EuVECA manager. It currently makes initial investments from its 2024 venture fund.

Lynx Financial founder identified in the organizer’s 2020 RESI investor biography. The primary 2024 Sachs European Life Sciences CEO Forum roster identifies him as Managing Partner, Lynx Financial Hong Kong Ltd. The manager’s homepage publishes no leadership titles, so Founder is used without asserting a newly verified 2026 executive title.

Named in Lynx Financial’s own public LinkedIn employee section. Exact job title is not published in the company directory.

Named in Lynx Financial’s own public LinkedIn employee section. Exact job title is not published in the company directory.

Head of technology and founder-team evaluation at Superhero; its own biography also identifies him as Cactos CTO and prior Eniram CTO/co-founder. The external company role is not transferred to Superhero.

Superhero senior advisor and CEO mentor; also described as a senior director at Nvidia. Nvidia title is not a Superhero executive role.

Named in Lynx Financial’s own public LinkedIn employee section. Exact job title is not published in the company directory.

Technology advisor specializing in strategy, infrastructure and data analytics; also described as a principal engineer at Nvidia.

Named in Lynx Financial’s own public LinkedIn employee section. Exact job title is not published in the company directory.

Andrew Ong is an embedded engineer whose current professional profile lists Clair Health and describes programming a wearable medical device in C. His engineering background includes embedded systems, electronics, digital signal processing and communications. The published professional descriptor supports this role; a senior management title is not inferred.

Emily Kraus, MD, is a Clair Health advisor, identified in her own attributed comments in the June2026 founder interview. She is a Stanford clinical assistant professor in orthopaedic surgery and a sports medicine physician focused on female athlete health. She directs the Female Athlete Science and Translational Research program. Her advisor comments describe research potential rather than established device efficacy.

Christy Lane, PhD, is an advisor to Clair Health, confirmed in her own public posts about the founders and financing. She is co-founder and co-CEO of FLORA fertility insurance. Her current FLORA biography describes seventeen years as a professor and prior founding experience with health-data company Vivametrica. She is a research and health-technology entrepreneur; her doctorate is not treated as an MD credential.

Haleigh Larson is Director of Partnerships and Communications at Clair Health. Her own public joining announcement and company posts identify her role supporting women’s health partnerships and communications. Further credentials and an exact appointment date have not been independently established.

Abhinav Agarwal is co-founder and CTO of Clair Health. In his direct founder interview he describes a background in wearable hardware and algorithms and the development of physiological signal models for hormone insights. His company-supplied founder photograph also shows co-founder Jenny Duan; Agarwal is the man on the left, and the original photograph is preserved without cropping.

Jenny Duan is co-founder and CEO of Clair Health, developing a wearable and AI models for women’s hormone insights. She studied symbolic systems at Stanford with an interest in AI ethics. Her own announcements describe the company’s founders, research and actual June2026 seed financing. Stanford’s CS25 course directory identifies her by name and links her exact professional profile.

Fabian Thehos is managing partner and co-chief investment officer of Wellcome’s in-house investment division. He joined Wellcome in2006 and previously led public-market investments including public equities, credit and hedge funds. He became managing partner inOctober2024 and co-CIO on1April2025. The original January2026 Wellcome bondholder presentation identifies his photograph and CFA qualification.

Lisha Patel is managing partner and co-chief investment officer of Wellcome’s in-house investment division. She joined Wellcome in2006 and previously oversaw private-market investments, notably property, infrastructure, private equity and venture capital. She became managing partner inOctober2024 and co-CIO on1April2025. The original January2026 Wellcome bondholder presentation identifies her photograph and CFA qualification.

The Wellcome Trust Limited is the active UK company limited by guarantee (company02711000, incorporated24April1992) that acts as sole corporate trustee of the Wellcome Trust, the independent charitable foundation established in1936 by Sir Henry Wellcome’s bequest (charity210183). This institutional profile identifies the exact trustee named in Alto Neuroscience’s convertible-grant financing, while describing its publicly branded Wellcome investment platform and governance. Wellcome invests its endowment across public equities, private equity, venture capital, property and other financial assets, using returns to support discovery research and health including mental health, neuroscience, infectious disease, climate and health. Its in-house investment division is led by managing partners and co-chief investment officers Lisha Patel and Fabian Thehos, with four published principals and a separate investment committee of staff, governors and external experts. Investment committee memberships are governance affiliations rather than claims that every member is an employee of the legal trustee. The1936 charity founding and1992 company incorporation are distinct. The reported GBP39.9billion investment portfolio is net portfolio value, not an externally closed venture fund. Wellcome does not publicly raise charitable donations; endowment assets, spending commitments, borrowing and conditional research-grant facilities are not treated as LP fundraising or fully funded cash. Alto’s USD2million funded execution tranche is separate from its conditional up-to-USD11.7million facility.

Martin (Marty) Mann is a Venture Partner at Cartan Capital. Its official biography identifies him as a USTA Foundation Advisory Board member leading its South Florida initiative, a founding partner at20/20 Healthcare Partners, and an M&A partner at Foley & Lardner. He studied at Stanford Law School and the Wharton School. Employment and board affiliations are distinct from personal cash investments.

Gordon Bellis is Partner and Chief Financial Officer at Cartan Capital. His official biography describes over35 years in finance, investment banking, investment management, and launching and managing hedge funds. He holds an MBA from UCLA and a master’s degree from the London School of Economics. His earlier funds are not assumed to be Cartan vehicles.

Georgie Sullivan is an Investment Analyst at Cartan Capital. Her official biography describes public health consulting, research and athlete wellness work, including development of an athlete wellness course for University of Nevada Division I students. She is a former Division I alpine skier and holds a public health degree from the University of Nevada, Reno.

CiCi Bellis is Founder and General Partner of Cartan Capital, which she founded in2023 after four years in venture capital. Her official biography describes her former professional tennis career, reaching WTA World No.35, her USTA Board of Directors role, and broadcasting for CBS Sports and Tennis Channel. She holds an MBA from the University of Miami and a business and finance degree from Indiana University.

Cartan Capital is an early-stage venture capital firm founded in2023 by CiCi Bellis. It invests at Seed and Series A across health technology, wellness, sports technology and human performance. Its current thesis includes healthcare AI, diagnostics, digital health, preventative care and personalized wellness. Its published portfolio includes Clair Health, Amplifier Health, NewDays, Springbok Analytics, Tiny Health, ai.io and Proto Hologram. Its official roster names CiCi Bellis, Georgie Sullivan, Gordon Bellis and Martin (Marty) Mann. Bellis confirms an oversubscribed USD10M Fund I raised within its first eight months. Contemporary coverage describes a deal-by-deal pledge structure; fund commitments are distinct from cash deployed or individual company tickets. Fund II began fundraising in2025 with a reported USD40M target; its final closed amount and closing date remain unverified. The exact brand, domain and founder establish this investor identity. A legal manager suffix and SEC CIK are not assumed from unrelated Cartan Holdings filings.

Hypertype is a Swedish AI company building support agents for manufacturing and industrial businesses. Its agents use a company’s own knowledge and operational data to answer technical questions, resolve service requests and retrieve documents for support, service and operations teams. The platform connects to customer relationship management software, helpdesk systems and internal tools so industrial staff can handle repetitive requests with less manual searching. Founded in 2021, Hypertype previously developed AI assistance for email and chat communications and now focuses its product on industrial support workflows.

Remos Space Systems develops software-defined satellite ground communications and ground-station infrastructure. Its Expedite and Hasten modems run on standard computing hardware, on premises or in the cloud, to handle satellite telemetry, telecommand and payload downlinks. The company also supplies turnkey ground stations and its Umoja platform for scheduling, automation and coordination across owned stations, third-party equipment and ground-station service networks. Its capacity-building programme combines ground communications, mission control, simulation infrastructure and training for space agencies, universities and emerging satellite programmes. Founded in Luleå in 2021, the company commercialises work originating at Luleå University of Technology.

His own public professional profile lists Remos Space Systems AB, also confirmed by the company’s public associated-person directory. The accessible primary text does not disclose a formal title.

Remos publishes Christer Andersson as a board member and Earth Observation Expert. The company also identifies him as L Christer Andersson on its LinkedIn page.

His public professional profile lists Remos Space Systems AB; Remos also names him in its 2025 team highlights. The accessible primary text does not disclose a formal job title.

Remos’s own employee spotlight, reposted on her public profile, identifies her as Administration & Finance Manager.

Remos’s own company post, publicly reproduced in an Orch repost, identifies Ivan Sedelkin as Software Engineer presenting the company’s paper at the November 2025 ESA TT&C workshop.

Remos’s employee spotlight describes work on high-data-rate system integration and customer installations. The public text does not disclose a formal job title.

Remos publishes Marcus Friman as a board member and identifies his background as co-founder of Netrounds.

Remos publishes Mustapha Elriz as a board member and identifies him as founder of Satconsult.

Remos identifies Omkar Nikam as host of its Space to Ground podcast in its June 23, 2026 episode. This published role does not establish a staff employment contract.

Remos’s employee spotlight describes work on partnerships, growth and commercial execution. The public text does not disclose a formal job title.

Remos publishes Stefan Gardefjord as a board member and former CEO of SSC.

Hypertype publishes Teenie Fung as CEO and co-founder. She also uses the professional name Teenie Fung Myhrman.

Former Enspire DBS Therapy summer intern and neuroscience researcher. Her own professional posts refer retrospectively to the internship; a2025–2026 research publication names the company affiliation. This role is historical, with exact tenure dates unpublished.

Clinical and scientific neuromodulation professional identified in the2019 Medical Device Innovation Consortium workshop as Enspire’s clinical/regulatory director and in the2020 EDEN protocol as a company contact. Current company position is not verified; the recorded role is historical.

Named author with an Enspire DBS Therapy affiliation in research on posterior-fossa spinal-cord stimulation leads, published online in2025 and in2026. This verifies a research affiliation, without inferring a permanent current employment title.

Publicly named as Vince O. in Enspire DBS Therapy’s own employee listing and the manager’s2026 investment announcement posts. Full surname and precise current position require additional primary verification; unrelated people named Vince Owens are not merged.

Enspire DBS Therapy team member whose own professional profile describes biomedical and clinical-psychology education at the University of Central Florida. Exact current job title is not publicly visible.

Named Enspire DBS Therapy employee in the company public professional-network listing. Exact current title and detailed biography are not published in the accessible company listing.

Named Enspire DBS Therapy employee in the company public professional-network listing. Exact current title and detailed biography are not published in the accessible company listing.

Enspire DBS Therapy team member, independently named in the company public employee listing and his own professional profile. Exact current title is not published in the accessible primary profile.

Medical-device professional affiliated with Enspire DBS Therapy. His own professional biography describes more than15years of device leadership and MIT Sloan management education. Company and manager public posts confirm team affiliation; the publicly visible primary profile omits an exact job title.

Enspire DBS Therapy team member with a background in business operations supporting bioscience and healthcare startups. Her own profile describes more than20years of operations experience and Baldwin Wallace education; exact current title is not publicly visible.

Team member publicly named by Treehub founder Mary Minno. Her exact linked personal profile lists Treehub; Giving Connection's own author biography identifies her as a Stanford computer science student in the class of 2029 working on technology and social impact. A precise Treehub investment or employment title is undisclosed.

Medical imaging and AI entrepreneur associated with Treehub's founder residency. Stanford's 2018 Arterys case study identifies him as that company's founder and CEO. Treehub's current own cohort announcement and its republished founder account identify programme support and a cohort-partner affiliation; this does not establish a fund general partnership. His authentic portrait is published by APIC's AI summit, which describes a historical executive affiliation with X.

Bioengineering researcher and team member publicly named by Treehub founder Mary Minno. The exact linked personal profile identifies Stanford bioengineering PhD studies; Stanford's Soh Lab independently lists her as a PhD candidate and publishes her named portrait. The accessible Treehub sources do not disclose an exact job title, tenure or employment arrangement.

Cleveland Clinic neuroscientist with more than25years of preclinical and clinical deep-brain-stimulation research. His lab translates neurostimulation approaches for acquired brain injury and movement disorders. Published2026 disclosures identify Enspire board, advisory and equity relationships; equity ownership is not treated as a cash investment.

Team member publicly named by Treehub founder Mary Minno. Stanford Medicine's Moonshot programme independently identifies him as a project lead in hospital medicine; its named portrait establishes the research identity. The exact Treehub job title and employment terms are unpublished, so no general-partner, CFO or full-time staff title is inferred.

Biomedical data science researcher and team member publicly named by Treehub founder Mary Minno. Stanford's own directory identifies her as a PhD student researching explainable AI, clinical data, machine learning and predictive modelling. A precise Treehub investing title has not been confirmed from accessible primary sources.

Neurosurgeon and neurostimulation researcher at Cleveland Clinic. His research helped establish the Enspire stroke-rehabilitation technology; published disclosures identify his company medical/scientific officer and board affiliations. Cleveland Clinic publishes his physician biography and authentic portrait.

Enspire DBS Therapy, Inc. is a Cleveland, Ohio medical-device company developing deep brain stimulation combined with structured rehabilitation for people with chronic upper-extremity impairment after stroke. Cleveland Clinic describes it as a spinout established in2010 to commercialize research by André Machado and Kenneth Baker. Its investigational approach stimulates cerebellar pathways to support rehabilitation and motor recovery. The company sponsors RESTORE, a multicenter pivotal PhaseII/III study, following the small EDEN feasibility study. The device is investigational and limited by United States law to investigational use; clinical studies and preclinical findings do not establish marketing approval or proven benefit for all patients. A January2026 SeriesB1 financing supports continued pivotal-trial enrollment. Publicly identifiable personnel include company staff, directors, scientific researchers and qualified historical advisors; a complete current employee directory is not published.

Chief executive of Enspire DBS Therapy, developing investigational DBS for stroke rehabilitation. His own professional profile describes medical-device technologies and implantable stimulation-lead development, with Boston University management education.

Almaral is a Finnish investment and business-support company founded in spring 2022 that backs early-stage biotechnology and life-science startups across Europe. Its investment partners combine financing with scientific, commercialization and operating expertise, supporting risk management, strategy, budgeting, company operations, sales and marketing, legal needs and international expansion. Its stated investment range is EUR 0.5–1 million and it expects board involvement; these are general criteria, not disclosed terms for individual investments. Almaral works with Hansdotter as its strategic marketing partner and Smartius as its legal-services partner.

Nostetta Ventures is a Kuopio-based Finnish venture fund manager backing pre-seed and seed companies with growth potential and strong connections to Eastern Finland. Founded in 2020 as a subsidiary of Nostetta Oy, it manages regional funds and builds co-investment syndicates, supporting technology commercialization, business development, financing and international growth. Its North Savo strategy includes health and wellbeing, cleantech, ICT, energy and technology companies; its South Karelia strategy is generalist with an emphasis on regional industrial innovation and the green transition.

Published in Nostetta’s own support roster as a Nostetta Oy parent-company team member who supports the manager and portfolio companies as needed; not an asserted Nostetta Ventures employee or board member.

Published in Nostetta’s own support roster as a Nostetta Oy parent-company team member who supports the manager and portfolio companies as needed; not an asserted Nostetta Ventures employee or board member.

Published in Nostetta’s own support roster as a Nostetta Oy parent-company team member who supports the manager and portfolio companies as needed; not an asserted Nostetta Ventures employee or board member.

Published in Nostetta’s own support roster as a Nostetta Oy parent-company team member who supports the manager and portfolio companies as needed; not an asserted Nostetta Ventures employee or board member.

Published in Nostetta’s own support roster as a Nostetta Oy parent-company team member who supports the manager and portfolio companies as needed; not an asserted Nostetta Ventures employee or board member.

Published in Nostetta’s own support roster as a Nostetta Oy parent-company team member who supports the manager and portfolio companies as needed; not an asserted Nostetta Ventures employee or board member.

Published in Nostetta’s own support roster as a Nostetta Oy parent-company team member who supports the manager and portfolio companies as needed; not an asserted Nostetta Ventures employee or board member.

Published in Nostetta’s own support roster as a Nostetta Oy parent-company team member who supports the manager and portfolio companies as needed; not an asserted Nostetta Ventures employee or board member.

Published in Nostetta’s own support roster as a Nostetta Oy parent-company team member who supports the manager and portfolio companies as needed; not an asserted Nostetta Ventures employee or board member.

Published in Nostetta’s own support roster as a Nostetta Oy parent-company team member who supports the manager and portfolio companies as needed; not an asserted Nostetta Ventures employee or board member.

Osney Capital is a UK venture capital firm focused exclusively on early-stage cybersecurity companies. It backs pre-seed and seed founders building technologies such as AI security, disinformation detection, identity governance and software supply-chain protection, typically joining rounds below GBP5 million. It writes initial cheques of GBP250,000 to GBP2.5 million, with capacity for Series A follow-ons, and helps founders through cyber-industry expertise, customer networks and commercial and regulatory experience. Its legal manager is Osney Capital LLP.

Volution invests in technology companies between early-stage venture capital and conventional growth equity, typically backing businesses with at least GBP5 million of annual recurring revenue. Its focus spans financial infrastructure, enterprise productivity software and AI, and the data and systems needed for agentic AI. The team provides capital and operational support for sales, international expansion, fundraising and acquisitions, drawing on networks across Europe and Asia. Its legal manager is Volution Ventures LLP; its second dedicated fund was launched with SBI Investment Co. through a co-general-partner arrangement.

Built startup ecosystems at MIT and NYU, worked in venture investing and university commercialisation and co-founded Osney Capital.

Supports founders with commercial scaling, brand and marketing, team development and global expansion. Founded Luxola, which was acquired by LVMH, led Sephora Southeast Asia and later served as Managing Director of LEGO Ventures.

Oversees portfolio monitoring and reporting and supports origination and investment execution. Previously worked at Estin & Co and Phoenix Equity Partners.

Leads portfolio strategy, governance, investment execution and underwriting. Previously invested in supply-chain ventures and led an early-stage Canadian venture fund focused on responsible consumption, food security and health.

Works on portfolio communications, limited-partner reporting, community and events. Holds an MBA from Copenhagen Business School and previously built a zero-waste consulting practice.

Combines operational and investment responsibilities. Previously worked at Freshfields and Lehman Brothers and was Head of Legal for EMEA at Neuberger Berman.

Leads investment strategy in financial infrastructure and enterprise AI. Has more than 25 years of private equity and venture experience, including senior roles at J.P. Morgan and Montagu.

Works with management teams on growth strategy and future funding. Was on the founding team at Star, helped MessageLabs expand internationally and founded Armada Ventures.

Known as Josh Walter; has held senior cybersecurity leadership roles and previously worked in financial services.

Known as Mike Edwards on the current directory. Works on deal origination, evaluation and execution; previously worked at Rolls-Royce, UBS Investment Bank and Redline Capital.

Supports governance and international growth, particularly in Asia. Former Head of Asia Pacific at Neuberger Berman, with earlier roles at Fidelity and J.P. Morgan.

Oversees operations, investor relations, portfolio development, brand and ESG. Previously held strategic and commercial roles at Christie’s.

Works on the founder platform, sourcing, fundraising, partnerships and business development. Previously founded an education technology business and advised Nordic technology companies on diversity and inclusion.

Financial services and regulatory lawyer with more than 15 years of experience, including eight years as a partner leading the corporate team at Collas Crill LLP.

Leads financial reporting, fund operations and impact framework development. Has more than 20 years of pension and investment experience and previously led sustainable investments at Velliv.

Assesses investments and supports commercial growth and partnerships. Co-founded Currencycloud and developed its relationship with Visa, which later acquired the business.

Leads fundraising, investor relations, portfolio management, due diligence, partnerships and fund operations. Previously worked in banking and sustainable finance and was a member of a UNEP FI sustainable banking working group.

Jeremy Langsam is Associate at Cleveland Clinic Innovations, according to its current public directory. A longer career biography was not available in the reviewed primary directory.

Todd Schwarzinger is a Partner at Cleveland Clinic Ventures. His own Clinic commentary describes aligning founders’ and strategic investors’ goals and culture and developing concise investment pitches; he publishes perspectives on healthcare technology and venture investing. His MBA credential is published by the Clinic.

Linda Li, CFA is a Partner at Cleveland Clinic Ventures, leading life-science and medtech portfolio strategy and AI-enabled digital-health investing. NeuroTherapia’s own director biography identifies her prior17-year Vickers Venture Partners co-founding-partner and investment-committee career across China, Southeast Asia and the US. She graduated from Peking University, earned a National University of Singapore master’s degree and is completing a doctorate at Johns Hopkins Bloomberg School of Public Health. Kauffman Fellows confirms the same Clinic/Vickers career and educational identity. She is distinct from Remiges Ventures’ Linda Li, whose own biography identifies a Princeton economics BA and Beth Israel leadership-board affiliation. Linda Li is venture partner at Eckuity Capital. Cleveland Clinic Ventures investment professional advising Eckuity on digital health, medical technology and health-system adoption. Distinct from the Remiges investor also named Linda Li.

Daniel Lee is Senior Director, Digital Health & Therapeutics at Cleveland Clinic Innovations, according to its current public directory. The directory publishes credentials JD, LLM. A longer career biography was not available in the reviewed primary directory.

Jerry Wilmink is Director, Digital Health at Cleveland Clinic Innovations, according to its current public directory. The directory publishes credentials PhD, MBA. A longer career biography was not available in the reviewed primary directory.

Linnea Gottlander is Manager, Innovations Governance & Contract Compliance at Cleveland Clinic Innovations, according to its current public directory. The directory publishes credentials JD. A longer career biography was not available in the reviewed primary directory.

Saqib Sachani, PhD, MBA is Director for Therapeutics and Diagnostics in Cleveland Clinic Innovations’ business-development and licensing team. His2024 Clinic profile describes his journey into commercialization and technology-transfer work; the current directory’s Director title supersedes that older Associate Director caption.

Zach Eisen is Senior Principal at Cleveland Clinic Innovations, according to its current public directory. A longer career biography was not available in the reviewed primary directory.

Bill Kolosi is Director, Medical Devices at Cleveland Clinic Innovations, according to its current public directory. A longer career biography was not available in the reviewed primary directory.

Giedre Ruzgaite is Associate Director, Digital Health & Therapeutics at Cleveland Clinic Innovations, according to its current public directory. The directory publishes credentials PhD, CLP. A longer career biography was not available in the reviewed primary directory.

Partha Paul is Director, Medical Devices at Cleveland Clinic Innovations, according to its current public directory. The directory publishes credentials PhD, MBA. A longer career biography was not available in the reviewed primary directory.

Joe Barone is Director, Therapeutics & Diagnostics at Cleveland Clinic Innovations, according to its current public directory. A longer career biography was not available in the reviewed primary directory.

Joseph Rich is Executive Director at Cleveland Clinic Innovations, according to its current public directory. The directory publishes credentials JD, MBA. A longer career biography was not available in the reviewed primary directory. JumpStart’s August2025 board-appointment biography describes nearly two decades leading innovation strategy, venture development, technology commercialization and regional economic-development initiatives. He leads the Clinic’s Ohio BioValidation Fund for early-stage healthcare technology investment. The current Clinic directory’s Executive Director title is retained separately from earlier Managing Partner captions.

Robin Crotty is Department Administrator at Cleveland Clinic Innovations, according to its current public directory. The directory publishes credentials MBA. A longer career biography was not available in the reviewed primary directory.

Shawn Zimmer is Senior Director, Finance at Cleveland Clinic Innovations, according to its current public directory. The directory publishes credentials CPA, MAcc. A longer career biography was not available in the reviewed primary directory.

Sonja O’Malley is General Manager, Business Development & Licensing at Cleveland Clinic Innovations, according to its current public directory. The directory publishes credentials MBA, PMP. A longer career biography was not available in the reviewed primary directory.

Jon David “JD” Friedland is Executive Director of Ventures at Cleveland Clinic Innovations. His healthcare-investment work follows investment banking and life-sciences advisory experience at Wombat Capital, Rothschild, Lazard Frères and Wasserstein Perella. Baleon Capital’s own adviser biography corroborates the full-name/initials identity and prior Henry Schein corporate/business-development and investment-platform work, plus a University of Southern California BS and Wharton MBA.

Michael Austriaco is General Manager, Assessment at Cleveland Clinic Innovations, according to its current public directory. The directory publishes credentials BSBA. A longer career biography was not available in the reviewed primary directory.

D. Geoffrey Vince is Chief of Cleveland Clinic Innovations and Chair of Biomedical Engineering. His research and leadership focus on aligning technology commercialization with clinical and scientific priorities, data and computing sciences. His virtual-histology technology was licensed to Volcano, later acquired by Philips. He earned a medical-sciences/chemistry degree at DeMontfort University and a biomedical-engineering PhD at the University of Liverpool.

Sarah Stamp is General Manager, Engagement at Cleveland Clinic Innovations, according to its current public directory. The directory publishes credentials MBA. A longer career biography was not available in the reviewed primary directory.

Prithraj Punia is an analyst at JobsOhio Ventures, supporting investment evaluation, portfolio analysis, financial modeling and market research. He joined the team in 2025. He earned an economics degree at Purdue University, with political-science and entrepreneurship studies. His direct joining announcement confirms the venture-unit affiliation; a more precise appointment date is not inferred.

Sachi Sanghavi is junior analyst at JobsOhio Ventures, supporting investment processes and research into prospective investments. She joined in 2025 after studying finance with an English minor at The Ohio State University. Her Ohio background spans the Cleveland, Cincinnati and Columbus regions. The exact manager-linked professional identity is distinguished from unrelated namesakes at Johns Hopkins and in India.

Stephanie Ison, also published as Steph Ison, is principal of JobsOhio Ventures. She brings operating, fundraising and acquisition experience from high-growth startups, private-equity-backed technology businesses and strategic consulting. Her background includes regional banking, Krush technology and media businesses, and founding Full Point Consulting in Dayton. She graduated from Wittenberg University.

Tatyana Hower is managing partner of JobsOhio Ventures and has worked with its evergreen venture platform since its 2020 inception. Her earlier career spans commercial banking and venture finance, including an emerging-technology lending group and BioEnterprise, where she helped medical-technology companies secure venture financing and led Medical Growth Fund activities. She graduated from Baldwin Wallace University and participates in the National Venture Capital Association CFO Taskforce.

Cleveland Clinic Innovations is the technology-commercialization arm of Cleveland Clinic, a nonprofit academic medical center operated by The Cleveland Clinic Foundation. Formed in2000, it advances caregiver inventions through assessment, technology development, intellectual-property protection, licensing, startup creation, strategic partnerships and venture investing. Its Cleveland Clinic Ventures team creates and invests in spinout companies and supports formation, management, governance, financing and strategic transactions. This profile represents the institutional commercialization and Ventures unit; public sources do not establish a separate independently capitalized venture fund manager. Its portfolio spans medical devices, diagnostics, therapeutics, digital health and artificial intelligence. Relevant examples include Enspire DBS Therapy’s stroke-rehabilitation neuromodulation, NeuroTherapia’s neuroinflammation therapies, AxoNeural’s spinal-cord-injury therapeutics, Infuseon’s brain drug-delivery catheter, Floreo’s virtual-reality developmental therapy, Bayesian Health’s predictive clinical AI and Dyania Health’s clinical-data AI. The current directory names20 leadership, business-development/licensing and Ventures staff. Chief D. Geoffrey Vince and Ventures Executive Director JD Friedland lead the commercialization and investing work. The Global Venture Philanthropy Fund is a donor-supported innovation program mentioned in Clinic publications; its size and close are not publicly disclosed in the reviewed sources, and it is not assumed to be a conventional closed LP venture fund. Healthcare-system assets, innovation outcomes, research budgets, licensing partnerships and venture capital committed to portfolio companies are not treated as manager fund-close cash. This unit is distinct from unrelated Cleveland Avenue and Cleveland Capital Management. Ohio’s2023 economic-development annualreport also names CCF Ohio BioValidation Funds I–VI as Foundation pre-seed investment capitalization vehicles, reporting state funds awarded, expenditures and cost share. Those figures and project-end dates are not treated as total LP commitments or fund-close dates. These government-backed capitalization vehicles and the philanthropic program are distinct from conventional closed LP venture funds.

Mihajlo Dordevic is published by machineMD as Test Engineer. The named role is in the company’s current public staff directory.

Nadine de Bernardi is published by machineMD as UX Design and Usability. The named role is in the company’s current public staff directory.

Principal machine-learning engineer at machineMD. Its December 1, 2025 introduction spells Jeroen; the current directory’s Jereon spelling is a typographical variant. PhD and published complexity/data-science background; no speculative prior employer role.

Michel Mürner is published by machineMD as Senior Software Engineer. The named role is in the company’s current public staff directory.

Gael Moccand is published by machineMD as Principal Software Engineer. The named role is in the company’s current public staff directory.

Requirements engineer at machineMD, introduced in April 2026. Own biography describes a neuroscience PhD from the University of Zurich and a health-sciences and technology background.

Permanent Capital Ventures is an early-stage venture firm that leads Series A investments in applied AI software and AI-enabled services. Founded by operators Mike Gamson and Jason Duboe, it backs technical founders who have established early product-market fit and helps them build enterprise sales, marketing, customer operations and revenue systems. The firm concentrates its investments so its partners can work closely with founders on distribution, recruiting and repeatable commercial growth.

Partner supporting investments and portfolio operations. Previously led LinkedIn revenue operations, served as Cameo’s COO and founded agricultural robotics business Farm-Hand.AI.

Chief operating officer with experience in alternative investment operations and finance. Previously served as GCM Grosvenor’s CFO and worked at Ernst & Young and Arthur Andersen.

Co-founded Permanent Capital Ventures following investment roles at Summit Partners and Chicago Ventures. Joined project44 as chief growth officer after backing the company as an investor.

Investment principal with experience at Valor Equity Partners, Hopper and GCM Grosvenor, spanning venture investing and corporate development.

Co-founded Permanent Capital Ventures after leading Evozyne and Relativity. Previously led LinkedIn’s global sales organisation and has invested in and advised early-stage companies.

Executive assistant supporting the investment firm’s leadership and operations, with prior executive support roles at GTCR and GCM Grosvenor.

Executive assistant with experience supporting senior leaders in investment banking, internet businesses, legal technology and biotechnology.

Investment principal focused on enterprise software, with prior roles at Emergence Capital, Regal, Bullpen Capital and Cloudflare.

Roland Peer is published by machineMD as Senior Requirements Engineer. The named role is in the company’s current public staff directory.

Cédric Madelaine is published by machineMD as Head of Usability. The named role is in the company’s current public staff directory.

Bruno Hauser is published by machineMD as Head of Analytics. The named role is in the company’s current public staff directory.

Marcus Zeiger is published by machineMD as Head of Software Engineering. The named role is in the company’s current public staff directory.

Christian Studer is published by machineMD as Head of Development. The named role is in the company’s current public staff directory.

Co-founder and chief product and innovation officer of machineMD. Leads development and innovation projects including the 2025 InnoCheque collaboration exploring a VR test for persistent postural perceptual dizziness.

Co-founder and chief technology officer of machineMD. Biomedical-engineering PhD; own history describes developing automated VR neuro-ophthalmic examination after collaborating with Mathias Abegg at Bern University of Applied Sciences.

Lara Nold is published by machineMD as Junior Scientific Collaborator. The named role is in the company’s current public staff directory.

Valérie Nydegger is published by machineMD as Clinical Research Assistant. The named role is in the company’s current public staff directory.

Léa Chabrowski is published by machineMD as Quality & Regulatory Affairs Manager. The named role is in the company’s current public staff directory.

Melina Maamir is published by machineMD as Clinical Affairs Manager. The named role is in the company’s current public staff directory.

Marginum is a Finnish medical-device company developing fluorescence-based tissue detection technology for cancer surgery. Its HIVEN aspirate tissue detector measures fluorescent tissue flowing through the surgical suction tube and gives neurosurgeons near-real-time auditory feedback, integrating with existing operating-room workflows. Its current EU MDR-certified intended use is fluorescence-guided surgery for suspected high-grade gliomas using 5-aminolevulinic acid. The company combines optical hardware and its FLUOSIGHT software to help distinguish tumour tissue during resection; it is expanding European distribution and conducting U.S. clinical studies while pursuing FDA authorization.

SeeTrue Technologies is a Finnish deep-tech company developing miniature, low-power eye-tracking hardware and embedded processing for smart glasses, AR and VR devices, medical optical systems and industrial applications. Its products include wearable gaze trackers, sensors integrated into microscope and telescope eyepieces, embedded smart-eyewear tracking, and hardware synchronization for large sensor networks. The company combines custom optics, miniature sensing hardware and on-device computation to deliver real-time gaze data within constrained power and size budgets, enabling gaze-based interfaces, attention measurement, training and research without requiring cloud processing.

University of Illinois neurosurgery professor and surgical technology specialist, serving on Marginum’s Executive Advisory Board.

Ilona Hubbard is published by machineMD as Senior Clinical & Medical Affairs Manager. The named role is in the company’s current public staff directory.

Founder of HyTest and life-science investor; Marginum lists her on its Executive Advisory Board.

Issuer’s August 2026 financing announcement identifies him as industry veteran, advisor, and new investor providing strategic execution support. No board seat or executive title inferred.

Cystotech develops CystoAID, an AI decision-support system for bladder-cancer diagnostics. The software analyzes cystoscopy video in real time and highlights suspicious tissue to support clinician assessment during initial diagnosis, surveillance and tumor-resection procedures. It runs on premises and integrates with existing cystoscopy equipment through a device-agnostic plug-and-play system. Founded by clinicians and software specialists in Aarhus, the company publishes MDR Class IIb medical-device certification and is developing commercial collaborations with European urology centers.

MedicQuant develops a point-of-care diagnostic platform that measures concentrations of small-molecule drugs directly from whole blood. Its first product targets direct oral anticoagulants in emergency stroke care, helping clinicians determine more quickly whether patients can receive treatment. The Aarhus University spin-out combines DNA nanotechnology, a disposable flow-front immunoassay cartridge and fluorescence readout, designed to provide laboratory-grade measurements in approximately 10 minutes. The platform is also being investigated for other drug measurements.

Ana Coito is published by machineMD as Senior Clinical & Medical Affairs Manager. The named role is in the company’s current public staff directory.

Certified urology nurse; leads operations and regulatory affairs.

Medtech entrepreneur; leads partnerships, commercialization and funding.

Certified urologist with a primary clinical focus on bladder cancer.

Sara Silvano is published by machineMD as Head of Regulatory and Quality. The named role is in the company’s current public staff directory.

Pia Massatsch is published by machineMD as Chief Scientific Officer. The named role is in the company’s current public staff directory.

Isabella Visarius is published by machineMD as HR Assistant. The named role is in the company’s current public staff directory.

Lena Arnold is published by machineMD as Head of HR. The named role is in the company’s current public staff directory.

Dina Kouznetsova is published by machineMD as Head of HR. The named role is in the company’s current public staff directory.

Nicolas Lachenal is published by machineMD as System Support & Operations Specialist. The named role is in the company’s current public staff directory.

Konstancja Maciejewska-Grünig is published by machineMD as Head of Operations. The named role is in the company’s current public staff directory.

Christoph Tschantré is published by machineMD as Commercial Director, Europe. The named role is in the company’s current public staff directory.

Avantika Naidu is published by machineMD as VP Business Development. The named role is in the company’s current public staff directory.

Phil Norris is published by machineMD as Chief Commercial Officer. The named role is in the company’s current public staff directory.

Co-founder and chief executive of machineMD. Leads commercialization of quantitative neuro-ophthalmic measurement using neos, VR eye tracking and digital biomarkers. Exact named responsible person in the Swiss company imprint.

Joseph F. Rizzo III is published by machineMD as Medical Advisory Board Member. The medical advisory directory associates this external adviser with Harvard Medical School; advisory service is distinct from company employment.

Konrad Weber is published by machineMD as Medical Advisory Board Member. The medical advisory directory associates this external adviser with University Hospital of Zurich; advisory service is distinct from company employment.

Tatiana Bremova-Ertl is published by machineMD as Medical Advisory Board Member. The medical advisory directory associates this external adviser with University Hospital of Bern; advisory service is distinct from company employment.

Neuro-ophthalmologist, co-founder, medical director and board member of machineMD. Own biography describes medical training in Zurich/Lausanne, electrophysiology PhD, clinical/research training in Canada, founding the Bern Eye Movement Laboratory and work in pediatric ophthalmology, strabismus and neuro-ophthalmology.

machineMD board member with published pharmaceuticals, ophthalmic device and market-access experience. Own biography describes Novartis, B. Braun and Zuellig Pharma roles and involvement with Nucleoptis and Von Hoff; historical biography does not independently verify every concurrent external role.

Life-science entrepreneur and machineMD board chair. Own biography describes ophthalmic device commercialization to CE mark and subsequent sale to Carl Zeiss Meditec; EPFL PhD and TU Darmstadt chemistry master’s. Prior investment, innovation-policy and operating experience is career context.

machineMD is the Swiss neurodiagnostics company machine MD AG, headquartered in Bern, with a Boston subsidiary. Its own imprint identifies Swiss register CH-036.3.079.921-3 and UID CHE-143.068.099. Founded in 2019 from University of Bern and Inselspital research, it develops neos, a headset and software system for standardized measurement of eye alignment, movements, pupillary responses and visual fields. Infrared eye tracking, virtual-reality visual stimuli and cloud reports provide quantitative neuro-ophthalmic data. Its research and machine-learning team explores digital biomarkers relevant to multiple sclerosis, Parkinson’s, Alzheimer’s and other brain disorders; research associations do not establish disease-specific screening accuracy or broad diagnostic authorization. The published TÜV SÜD EU MDR certificate covers the NEOS head-mounted display and software as a Class IIa device, valid from October 7, 2024. Its June 2026 issuer article describes US FDA Class I registration, which is recorded as a company-stated registration claim and not FDA approval or clearance. The complete published directory contains four board members, four external medical advisers and thirty named team members; listed concurrent HR leadership is preserved as published rather than assuming a departure. Financing includes the contemporary December 2021 CHF1.4M convertible-loan closing, September 2022 CHF3.2M seed led by Guido Fluri Foundation, and Topcon Healthcare’s March 2025 pre-Series A investment. A later CHF1.2M description of the 2021 note is a conflicting retrospective conversion figure, not additional cash. Collaborative research grants are recorded with unknown company allocations; consortium budgets, grant programme caps and proposed round targets are not machineMD proceeds.

JobsOhio Ventures is the evergreen co-investment venture platform and subsidiary of JobsOhio, Ohio’s private nonprofit economic-development corporation. It invests alongside qualified institutional lead investors in early-stage healthcare and enterprise-technology companies with an Ohio operating connection, primarily from Series A onward, using direct equity and convertible debt. Its current website describes a USD250 million evergreen fund platform, patient capital across commercialization milestones and no portfolio-company board seats. This stated program capacity is not a separately dated pooled-fund closing or disclosed cash draw. The platform previously operated as the JobsOhio Growth Capital Fund; the parent’s former program URL redirects to JobsOhio Ventures, and its managing partner has served since the 2020 inception. The published portfolio includes neural-haptics company Afference, neurostimulation companies Enspire DBS Therapy and Neuros Medical, medical-imaging and clinical AI companies, and semiconductor security company Niobium. The venture unit is distinguished from JobsOhio’s broader grants, loans and economic-development programs, and unrelated syndicate partners are not investments in those fund managers.

Arif A. Wani is identified as a General Partner at Oxford Seed Fund byan event he co-hosted withOpenseedVC, and as Head ofOxford Seed Fund bythe Oxbridge AI X community. Oxford Saïd’s2024–2025 primary impact report identifies him as Head ofInvestment and supplies his named photograph. No exact appointment date or personal portfolio check is inferred.

James Henry Wilkinson is a director of OSF Manco Limited, the legal entity named byOxford Seed Fund’s current website. Companies House records his appointment on30January2026. He signed the2026 OSF I LP registration for OSF I GP LLP and OSF Manco Limited. A presumed alias with other investors named Jim Wilkinson is not used without independent identity proof. Xfund publishes Jim Wilkinson in its faculty/advisory roster, with a source-aged Oxford Science Enterprises interim-CEO/CFO caption. Primary Oxford sources identify the finance executive publicly as Jim; Companies House legal profiles identify James Henry Wilkinson across Oxford Science Enterprises and OSE Manager Limited. Matching legal identity particulars and the Oxford finance/entity chronology support reuse of this existing OSF Manco director, rather than creating a second Jim profile. The OSE/OSE Manager directorships ended31March2026; the undated Xfund caption is not proof of a current interim CEO/director job.

Has been an Alto director since October 2023 and president and CEO of the NIHCM Foundation since October 2025. Previously led Blue Cross Blue Shield of Massachusetts and served on Ironwood’s board. His experience spans health insurance, healthcare leadership and nonprofit governance.

Has been an Alto director since April 2022 and CEO of Lightswitch Capital since December 2021. His experience includes financial services, asset management, entrepreneurship and corporate law. He studied law at NYU and politics at Princeton.

Has been an Alto director since September 2021. Co-founded Lighthouse Capital Partners and was its founding managing director until 2017. Her current Alto biography also identifies a Sofina board role and nonprofit trusteeships. She holds Harvard undergraduate and MBA degrees.

Clinical professor of computational psychiatry at University College London and deputy director of the Max Planck UCL Centre for Computational Psychiatry and Ageing Research. His training combines medicine, computational neuroscience and machine learning, with prior clinical and research work in Zurich.

Alto Neuroscience, Inc. is a publicly listed, clinical-stage biopharmaceutical company developing precision treatments for neuropsychiatric disorders. Founded in 2019 by psychiatrist and neuroscientist Amit Etkin, its machine learning platform combines EEG brain activity, computerized cognition tests, wearable sleep and activity data, and clinical datasets to identify patient groups more likely to respond to particular drug candidates. Its investigational pipeline addresses major depressive disorder, treatment-resistant depression, bipolar depression and schizophrenia. The platform supports biomarker selection and drug development; the company’s candidates remain investigational. Alto completed its NYSE ANRO initial public offering in February 2024, followed by institutional private placements and a July 2026 registered direct offering. It is headquartered in Mountain View, California.

Has been Alto’s chief medical officer since July 2021. Previously led clinical neuroscience research at Janssen and held psychiatry faculty and clinical roles at Weill Cornell and Massachusetts General Hospital. He holds medical and molecular biology doctoral degrees from UCLA and a Yale biophysics and biochemistry degree.

Founded Alto in 2019 after a career as a tenured Stanford professor of psychiatry and behavioral sciences. His clinical neuroscience laboratory also worked at the Palo Alto Veterans Affairs Medical Center. Alto’s current biography identifies him as founder, chief executive and board chair.

Co-founded Alto and has been a strategic adviser since November 2023, after serving as COO, chief strategic officer and director. Previously co-founded Brain Resource, later Total Brain, and worked in healthcare strategy and equities analysis. He studied physics and accounting at Australian universities.

Has led Alto’s legal and administrative functions since February 2023. Previously held legal leadership positions at Levo Therapeutics, Assertio, Mead Johnson, Hyatt and SPSS. She holds a Georgetown law degree and Duke public policy degree.

Became Alto’s chief development officer in September 2023 after leading clinical operations. Earlier managed clinical development at Alkahest, Bioclinica and SRI, including Alzheimer’s and Parkinson’s trials, and managed a Stanford neuroscience laboratory. She studied biology at Texas A&M.

Alto adviser and University of Texas Southwestern psychiatry professor. Leads its mood disorders division and founded its Center for Depression Research and Clinical Care. His training includes Baroda Medical College, Henry Ford Hospital and advanced imaging and psychopharmacology research at UT Southwestern.

Joined Alto as COO in May 2024. His CNS pharmaceutical leadership experience includes commercial and business roles at Aeglea, Horizon and Lundbeck, across psychiatry and neurological diseases. He holds Notre Dame and Northwestern Kellogg degrees.

Became Alto’s president in August 2026 and has been its CFO since November 2022. Previously chief business officer at Alto, he earlier worked in corporate development and investor relations at Aptinyx. He holds an accounting and finance degree from North Central College.

Psychiatrist and neuroscientist advising Alto. Former director of the US National Institute of Mental Health, he previously worked at Emory and led mental healthcare technology efforts at Verily. He co-founded Mindstrong Health and is a member of the National Academy of Medicine. Tom Insel is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: Former head of the National Institute of Mental Health; former mental health lead at Verily. This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Michael Hutson is a Partner at Oxford Seed Fund and an Associate Fellow at Oxford Saïd Entrepreneurship Centre. His2026 published biography describes investing inOxford student and alumni founders and an interest inquantitative venture capital. Companies House identifies him as Michael David Hutson, an OSF Manco Limited director appointed30January2026.

Oxford Seed Fund (OSF) backs early-stage technology companies founded by Oxford-affiliated students and alumni worldwide. Its current osfvc.com website identifies the legal manager as OSF Manco Limited, company17004218, incorporated inEngland on30January2026. The brand has a longer history as a student-led Saïd Business School entrepreneurship programme: the school dates its launch to2013, while OSF’s own LinkedIn lists2012. The current manager and the university’s Venture Capital Lab are legally and operationally independent. Relevant verified backing includes Bridge Neurotech’s research into a non-invasive ultrasound brain interface; historical programme investments include mental-health AI company Allia Health, cellular-therapy automation company Limula, sleep-monitoring company Albus Health, and AI and satellite-computing businesses. InAugust2023 the university programme raisedGBP2.5M from Oxford Science Enterprises; that historical allocation is not attributed as a closing of the new2026 legal manager. Companies House confirms OSF I LP (LP024666), registered22July2026, with OSF I GP LLP as general partner and OSF Manco Limited as limited partner. Its capital size and fundraising close are not publicly established. The manager’s current site is a coming-soon page and does not publish a complete team or portfolio directory; verified public investment leaders and legal directors are recorded with their specific sources, while historical student cohorts are distinguished from current employees.

Beau Woodward is named as a GreyscaleAI director in the January23,2025 SEC offering disclosure. No unverified other employment, personal investment ticket or current2026 tenure is inferred from that dated public filing.

Brynne Kennedy is named as a GreyscaleAI director in the January2025 SEC filing. Smart Society Capital’s own biography identifies her as co-founder and managing partner, former co-founder/CEO of Topia, a Yale history graduate and London Business School MBA. A director role does not establish an individual investment ticket or identify the manager buying any specific company financing.

Stephen Doyle is named as a GreyscaleAI Executive Officer and Director in the October2023 SEC filing, and a director in the September2022 amendment. The company’s public filings do not specify an exact executive title; no CEO title, personal investment or current2026 tenure is inferred.

Stephen Shueh is named as a GreyscaleAI director in the September2022 SEC amendment. The December2022 filing reverses first/last names as Shueh Stephen; the issuer, board context and filing history support treating this as the same dated director rather than creating a reversed-name duplicate. No investment ticket or unverified current employment is inferred.

Don Fotsch is named as a GreyscaleAI Executive Officer and Director in March2022. A2020 QuantumMetric interview identifies him as company co-founder and Chief Product Officer. Battery Detection Solutions AI’s own current biography confirms earlier Greyscale AI experience and prior Apple, PayPal and John Deere work. No current Greyscale executive tenure is inferred.

Rich Cisek is named as a GreyscaleAI Executive Officer and Director in its September2022 SEC amendment. Battery Detection Solutions AI’s own current biography identifies his high-resolution X-ray hardware and AI cloud/edge inspection work; LineWise’s own published biography also identifies Greyscale AI among the inspection startups he led. This company affiliation is dated, not asserted as current2026 management.

Mike Dennis is named as GreyscaleAI’s Senior Vice President of Sales and Marketing in its formerly published management biography, which describes30 years developing complex consumer-packaged-goods solutions and BA/MS degrees from Michigan State University. The original team URL now redirects to a404 page; this is a historical published affiliation, not verified current2026 employment.

GreyscaleAI, Inc. is a Delaware-incorporated industrial inspection company founded in 2020. Its HRX high-resolution X-ray systems and application-specific artificial intelligence inspect food, beverages and packaged products for foreign material, seal integrity, product trapped in seals, dents, weight and counts. The Insights analytics platform provides image histories, inspection events, trends, alerts and machine-health data; managed inspection and support services complement the hardware and software. Its current contact page lists Tarpon Springs, Florida; earlier company material lists Fremont, California. The technology is relevant to computer vision, industrial AI and deep tech, rather than a dedicated neuroscience or medical brain-imaging platform. Brian Green is confirmed as CEO by a June2026 industry event. The current website has no named team directory; older management biographies and SEC officer/director disclosures are retained with explicit dates. Seven distinct SEC equity offerings report USD26,048,012 sold through January2025. This is a sum of disclosed offering snapshots, not an independently verified lifetime cash balance or announced venture-stage total. The September2022 amendment supersedes the March2022 original; offering targets and rumored incremental rounds are excluded. APA Venture Partners lists the company in its own portfolio, without establishing a particular financing round, lead status or individual ticket. This company is distinct from UK neuromorphic drone company grayscale.ai and Grayscale cryptocurrency asset management.

Brian Green is CEO of GreyscaleAI, confirmed by the organizer of the June2026 Foreign Material Forum. Its formerly published management biography describes more than20 years of AI and computer-vision work at Accenture, a BS and MS from the University of Florida and a PhD from the University of Virginia.

Bob Burns is publicly affiliated with Glenview Capital and is named as an executive officer of GCM Investment Partners in a January2026 SEC filing. His self-published professional profile confirms Glenview affiliation, Yale University education from2003 to2007 and CFA and CAIA qualifications. His exact manager job title and an accessible authentic portrait are unverified; he is distinct from similarly named politicians and other financial professionals.

Biotechnology entrepreneur and individual investor. She cofounded 23andMe in 2006; 23andMe Research Institute's current own governance directory identifies her as founder and CEO of the nonprofit institute. Treehub's 2026 launch interview identifies an operating-partner affiliation. Clair Health's transaction counsel separately names Anne as a personal investor in its June 2026 seed financing; that individual check is distinct from Treehub's fund participation and from corporate investment by 23andMe.

Adam Jake Sangster, also published as Jake Sangster, is associated with Intermountain’s venture platform. A previously indexed official AAFP trustee biography described him as an operating principal working on company commercialization, digital-health growth, primary-care strategy and partnerships, with healthcare administration studies at BYU–Idaho and health-policy studies at Penn State. The January2026 AAFP announcement independently confirms his public-trustee status, but does not state his current venture-unit seniority. The migrated current board page omits the old biography, and its authentic former portrait URL returns404. His exact current unit title and portrait therefore remain explicitly unverified.

Dakota Hansen is an investment analyst at Intermountain Ventures in his published Flare Capital biography. His work includes healthcare investment diligence, pipeline development, stakeholder engagement and mentoring interns; the biography names Rula and Stepful investments. He previously worked with Pelion, Peak and Neighbor Growth. He earned information-systems and finance qualifications at the University of Utah and played on its football team.

David Hadley is publicly associated with Intermountain Ventures and identifies Intermountain Health on his own professional profile. A Boise State account of the 2020 Utah investing conference names him as an Intermountain Ventures mentor. His public profile describes innovation, commercialization and mentoring work and Claremont Graduate University education. No exact current venture-unit title or authentic public portrait was independently verified.

Dustin Cook is managing director and partner at Intermountain Ventures, confirmed by the 2025 Innovation Summit organizer and current venture-unit posts. His experience covers medical devices, insurance, healthcare delivery and startups. He evaluates strategic investments and supports healthcare innovation. His authentic portrait is published by Flare Capital in its scholar-alumni directory; that older biography is not used as evidence of his current title.

Frits Jonker is publicly associated with Intermountain Ventures. Flare Capital’s biography describes him as a senior investments associate, working on healthcare investment diligence, portfolio support and analyst mentoring. It names investments including Octave, Freenome, Vori, cTRL, SomaLogic, Foodsmart and Leiters. He previously worked in Goldman Sachs investment research on medical technology and studied at Baylor. His published seniority is retained with a qualification because a current unit roster is unavailable.

Landon Browning is an associated employee listed on Intermountain Ventures’ own public page. His matching profile identifies the Intermountain affiliation and Weber State education. He lists financial-services credentials on that profile; these are not represented as independently verified current regulatory registrations. His precise current unit responsibilities and an authentic public portrait were not established.

Nathan Jones is listed as an associated employee on Intermountain Ventures’ own public company page. His matching public profile identifies the Intermountain affiliation and University of Texas at Austin education. A current official biography, precise unit title and authentic public portrait were not verified. He is not merged with the similarly named Nevada physician or other unrelated professionals.

Skyler VomDorp is Mindshare Institute’s chief financial officer. His own current biography states that, since joining Intermountain in 2022, his accounting and finance responsibilities have supported Mindshare Institute, Intermountain Ventures and selected portfolio companies. His Mindshare CFO title is not represented as the venture unit’s CFO title. He has banking, accounting and treasury experience, Westminster business qualifications, and published CPA and treasury credentials.

Nickolas Mark co-founded Intermountain Ventures and serves as managing partner, as identified in his published conference and BioUtah biographies. He works on strategic healthcare investments, corporate development and commercialization. His biography describes prior investment-management and consulting experience; the assets managed by a previous employer are not attributed to Intermountain Ventures.

Lloyd Mandell is a managing director at Glenview Capital, involved in corporate development, its investment committee and private investments. His published Quanta director biography describes more than25 years of public and private market investing focused on healthcare, prior leadership of Coeus Capital and roles at Davidson Kempner, Carlson Capital and Roystone Capital. He graduated from the University of Pennsylvania’s Management and Technology dual degree program. His self-published profile additionally describes chief digital officer duties.

Appointed Topcon Healthcare chief strategy and business development officer in December 2024; subsequently named in its 2025 IRIS acquisition announcement. Previously vice president of healthcare strategy, partnerships and M&A at Microsoft with Nuance and GE Healthcare experience. October 6, 2026 issuer appoints him to the corresponding role at separate Oku Digital Health; continued Topcon tenure is not expressly confirmed.

Leslie C. M. Amodei is named as Topcon Healthcare vice president of marketing for Americas in issuer media contacts, including its 2026 announcements. Ophthalmic and medical-device marketing background. Her authentic named portrait is from a historical 2007 interview and is explicitly not represented as a current photograph.

Former Topcon Healthcare corporate venture capital operations lead and investment principal. His own 2026 departure announcement describes two years supporting healthcare AI, ophthalmology, diagnostics and digital-health investments and launching Nuvisy Strategic Advisory. His older personal website still lists Topcon; the newer explicit departure takes precedence. Actual departure day is unknown. No personal investment check inferred.

Topcon Healthcare head of digital health solutions and clinical development in EMEA, appointed in May 2025. Leads the regional THINC initiative, with published prior experience in ophthalmic technology, clinical development and education at Heidelberg Engineering. Regional role distinguished from Topcon Europe Medical corporate leadership.

Topcon Healthcare general counsel and chief data protection officer, confirmed by his 2026 Stanford conference speaker biography. Privacy, data governance and AI transactions background; prior leadership at Blackhawk Network, Yahoo, TrustArc and Avellino Lab. George Washington University JD and Maryland Bar membership.

Ophthalmic physician-scientist appointed Topcon Healthcare chief medical officer in April 2025. Previously principal medical director in Genentech ophthalmology, with retinal-imaging AI and clinical-development expertise. October 6, 2026 issuer appoints her chief medical officer of separately launched Oku Digital Health; ongoing concurrent Topcon tenure is not expressly confirmed.

Topcon Healthcare, Inc. is a US medical-device and digital-health company within Japan-based Topcon Corporation. The parent’s securities report traces this exact US unit to Topcon Instrument Corporation of America, established in 1970; the parent’s 1932 founding is a different entity. The company supplies ocular imaging, OCT, diagnostic and examination equipment and the Harmony cloud platform. Its Healthcare from the Eye initiative uses retinal imaging, ocular functional data and artificial intelligence to support research, disease detection and connected care, including systemic and neurological conditions. THINC combines incubation, clinical and regulatory support and corporate strategic investment. Its own September 9, 2025 announcement names this unit as Senseye’s strategic investor; Senseye’s investigational mental-health assessments are company-stated development goals, not independently established diagnostic performance. Other primary investment announcements include RetiSpec, machineMD, Pangaea Data, EYE-GO, Ocumetra, Sanro Health, Cascader and ocular-AI Toku, distinct from the unrelated fintech Toku. This is the corporate investing unit, not the Japanese parent or an independently verified institutional LP fund. An interview with its venture principal describes balance-sheet financing; no actual unit cash raise, IPO or closed pooled venture fund has been verified. On October 6, 2026 the unit launched the separate Oku Digital Health company. That release explicitly retains Ali Tafreshi as Topcon Healthcare CEO and Lance Patton as president; it does not establish that every leader appointed at Oku continues a Topcon role. Team records therefore distinguish currently confirmed leadership, last-confirmed historical appointments and a confirmed former venture principal. The company does not publish a complete current personnel directory.

AI Health Fund is an early investment platform backing computational approaches to health, including healthcare AI, precision outcomes and scientific technologies. It built Treehub, an invite-only founder residency in Los Altos, California that combines first-check investing, company-building support and access to clinical and academic networks. The fund's own directory publishes Mary Minno, Alexander Ioannidis, Derek Minno, Roxana Daneshjou and Esther Wojcicki. Treehub's own site names Clair Health, Nestwell and Will Biederman's non-invasive brain-computer-interface company among first-check investments; Bridge Neurotech's own site and Treehub's current announcement establish the last identity. This profile represents the published combined investment platform and uses Treehub's official program branding. Exact legal manager registration, complete current staff, final fund close and aggregate committed capital remain unverified. It is distinct from Bellevue's listed AI healthcare equity funds and from Point Capital, whose website links to AI Health Fund.

Biomedical data science researcher, published as Alex Ioannidis in AI Health Fund's own team directory. The directory identifies a scientific affiliation with the fund and describes his Stanford research and Galatea Bio cofounding background. The title recorded here does not infer a general partnership or full-time investing appointment.

Investor and partner associated with Treehub by AI Health Fund. The fund's own directory describes venture-investing and fund-management experience. Point Capital's own website separately identifies him as its president and links to AI Health Fund; those outside roles do not establish that the two investment platforms are the same legal manager.

Educator and author associated with Treehub by AI Health Fund. The fund's own directory publishes her as part of its team; her launch interview identifies a founding-advisor affiliation. This advisory role is distinct from a managing partner or staff executive appointment.

Founding partner of Treehub, the AI Health Fund's residency and early investment platform for health-focused AI founders. Her own professional profile describes product leadership at Google and Meta and entrepreneurship before Solvvy. The fund's own directory publishes her operating background.

Physician and biomedical data science researcher listed in AI Health Fund's own team directory. Treehub's own published August 2026 event announcement identifies her as a founding investor. The fund describes her dermatology and biomedical data science research background; clinical and university affiliations are background rather than added external roles.

55 North is a Copenhagen-based venture capital firm dedicated to quantum technologies. It invests across quantum computing hardware and software, communications, sensing, timing and the enabling components needed to commercialise quantum systems. Its mandate spans early-stage research ventures through growth companies, combining a European and Nordic focus with the ability to invest globally. The investment team pairs scientific and engineering experience with venture capital expertise to help businesses translate quantum research into industrial applications, including advanced computing, artificial intelligence and drug discovery. Its first fund completed a EUR134 million first close in October 2025 toward a EUR300 million target, anchored by Novo Holdings and Denmark’s Export and Investment Fund.

Computational physicist with experience across academic research, industrial technology, optimisation and quantum systems.

Experimental physicist and engineering leader with experience designing, building and scaling quantum technologies, systems and products.

Deep technology investor and physical organic chemist with experience leading research and development and venture investments.

Delphinus Venture Capital is an Aarhus-based evergreen investor backing research-intensive Danish startups in food, health, defence and energy. It invests from pre-seed through Series B and reserves capital for follow-on rounds, providing long-term support as scientific and engineering ideas develop into businesses. The firm typically begins with EUR100,000 to EUR1 million investments in Danish-incorporated companies and can invest up to EUR10 million per company over time. It was launched in 2025 by Aarhus University Research Foundation, HEARTLAND, Norlys and Salling Group with DKK600 million of capital, combining university research connections with industry expertise. The actual legal evergreen investment vehicle identified by the own site CVR45630242 is Delphinus Venture Capital K/S. Its audited2025 annual statements, adoptedJune10,2026, separately identify general partner Delphinus Venture Capital GP ApS (CVR45615480) and management company Delphinus Forvaltning ApS (CVR45614662). The branded institutional profile preserves the actual existing portfolio buyer and qualifies these separate legal functions; no parent/manager/vehicle duplicate financing checks are created. The current public directory identifies seven people and Mathias Brink Lorenz as Managing Partner and CEO; the accounts document him signing on behalf of the general partner. Portfolio biography Jörg Weiser’s Executive Chairperson/Interim CEO title belongs to Kvantify, not this fund manager, and is not assigned as Delphinus employment. The existing DKK600M evergreen fund record and Aug12,2025 public launch announcement are retained; sponsor Salling Group confirms its100M contribution is included in that total. Announced fund capital is distinct from paid-in capital, current NAV, commitments to portfolio loans and statutory corporate capital. Authentic original name-bound portraits have now been filled for all seven current professionals while existing biographies, roles, logo, fund values and investor checks are preserved.

Works on health and energy investments, drawing on experience in strategy, communications and partnerships, including leading Danish Industry’s startup activities.

Supports early-stage investments while pursuing an MSc in Innovation Management at Aarhus BSS.

Works with early-stage technology founders, with prior experience in investment banking, venture capital and a venture-backed startup.

Leads the firm with experience across venture capital, mergers and acquisitions and investment banking; previously an investment director at the European Circular Bioeconomy Fund.

Supports investment analysis with experience spanning venture capital, restructuring and board advisory.

Supports early-stage investment analysis while pursuing an MSc in Finance and International Business at Aarhus BSS.